10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

     (MARK ONE)

[X]      QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2003 or

[  ]      TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number    000-30941

AXCELIS TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

 

Delaware	34-1818596
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

55 Cherry Hill Drive
Beverly, Massachusetts       01915
(Address of principal executive offices, including zip code)

(978) 787-4000
(Registrant's telephone number, including area code)

    Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   YES [X] NO [  ] .

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes [X] No [  ].

As of August 12, 2003 there were 98,898,558 shares of the registrant's common stock outstanding.

AXCELIS TECHNOLOGIES, INC.
FORM 10-Q
INDEX

PART I. FINANCIAL INFORMATION

PART II. OTHER INFORMATION

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Axcelis Technologies, Inc.
Consolidated Statements of Operations
(In thousands, except per share amounts)
(Unaudited)

	Three Months Ended						Six Months Ended
	June 30,			June 30,			June 30,			June 30,
	2003			2002			2003			2002
Net sales	$	84,671		$	88,988		$	167,076		$	151,073
Cost of products sold		57,655			55,760			112,385			102,448
Gross profit		27,016			33,228			54,691			48,625
Operating expenses:
Research and development		15,927			18,572			32,103			36,284
Selling		11,509			11,742			23,607			22,980
General and administrative		9,099			11,673			19,542			23,620
Amortization of intangible assets		365			365			730			730
Loss from operations		(9,884	)		(9,124	)		(21,291	)		(34,989	)
Other income (expense):
Royalty income		1,258			3,354			3,023			3,921
Equity income of Sumitomo Eaton Nova Corporation		1,298			3,322			4,493			1,360
Interest income		523			1,019			1,054			1,976
Interest expense		(1,409	)		(1,696	)		(2,787	)		(2,894	)
Other-net		(719	)		(1,283	)		(1,002	)		(1,644	)
Loss before income taxes		(8,933	)		(4,408	)		(16,510	)		(32,270	)
Income taxes (credit)		69,945			(2,731	)		68,694			(12,762	)
Net loss	$	(78,878	)	$	(1,677	)	$	(85,204	)	$	(19,508	)
Basic net loss per share	$	(0.80	)	$	(0.02	)	$	(0.87	)	$	(0.20	)
Diluted net loss per share	$	(0.80	)	$	(0.02	)	$	(0.87	)	$	(0.20	)
Shares used in computing:
Basic net loss per share		98,289			97,876			98,284			97,846
Diluted net loss per share		98,289			97,876			98,284			97,846

      See accompanying notes to consolidated financial statements.

Axcelis Technologies, Inc.
Consolidated Balance Sheets
(In thousands)
(Unaudited)

		June 30,			December 31,
		2003			2002
ASSETS
Current assets:
	Cash & cash equivalents	$	116,622		$	150,651
	Short-term investments		36,926			34,992
	Accounts receivable		73,227			60,311
	Inventories		110,424			115,290
	Deferred income taxes & other current assets		2,944			18,329
Total current assets			340,143			379,573
Property, plant & equipment, net			90,015			93,597
Investment in Sumitomo Eaton Nova Corporation			61,892			57,868
Goodwill			40,682			40,682
Intangible assets			12,411			13,141
Deferred income taxes			—			57,136
Other assets			28,294			27,454
Total assets		$	573,437		$	669,451
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
	Accounts payable	$	29,262		$	32,594
	Accrued compensation		6,744			6,745
	Warranty reserve		14,948			16,625
	Income taxes payable		7,486			12,823
	Other current liabilities		17,686			18,400
Total current liabilities			76,126			87,187
Convertible debt			125,000			125,000
Other long-term liabilities			2,979			4,756
Stockholders’ equity:
	Common stock		99			98
	Additional paid-in capital		448,659			447,533
	Deferred compensation		(1,080	)		(782	)
	Treasury stock - at cost		(1,218	)		(1,218	)
	Retained earnings (deficit)		(72,835	)		12,369
	Accumulated other comprehensive income (loss)		(4,293	)		(5,492	)
Total stockholders’ equity			369,332			452,508
Total liabilities and stockholders’ equity		$	573,437		$	669,451

      See accompanying notes to consolidated financial statements.

Axcelis Technologies, Inc.
Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

		Six Months Ended
		June 30,
		2003			2002
Operating activities:
	Net loss	$	(85,204	)	$	(19,508	)
	Adjustments required to reconcile net loss to net cash used by operating activities:
	Depreciation and amortization		5,856			5,320
	Amortization of intangible assets		730			730
	Stock compensation expense		85			312
	Deferred income taxes		73,685			(16,201	)
	Equity income of Sumitomo Eaton Nova Corporation		(4,493	)		(1,360	)
	Changes in operating assets & liabilities:
	Accounts receivable, net		(11,853	)		(4,880	)
	Inventories		6,243			(421	)
	Other current assets		(1,153	)		(1,175	)
	Accounts payable and other current liabilities		(6,412	)		6,874
	Income taxes payable		(5,340	)		—
	Other assets		(1,019	)		354
	Other-net		(1,777	)		161
Net cash used by operating activities			(30,652	)		(29,794	)
Investing activities:
	Purchases of short-term investments-net		(1,934	)		(12,477	)
	Expenditures for property, plant & equipment		(2,170	)		(8,883	)
	Other-net		75			(84	)
Net cash used by investing activities			(4,029	)		(21,444	)
Financing activities:
	Proceeds from long-term debt-net		—			121,578
	Proceeds from the exercise of stock options		—			104
	Issuance of common stock from Employee Stock Purchase Plan		743			2,736
Net cash provided by financing activities			743			124,418
Effect of foreign exchange rate changes			(91	)		1,402
Net increase (decrease) in cash & cash equivalents			(34,029	)		74,582
Cash & cash equivalents at beginning of period			150,651			124,177
Cash & cash equivalents at end of period		$	116,622		$	198,759

      See accompanying notes to consolidated financial statements.

AXCELIS TECHNOLOGIES, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
SIX MONTHS ENDED JUNE 30, 2002

1)      Nature of Business and Basis of Presentation

Axcelis Technologies, Inc. ("Axcelis" or the "Company"), is a worldwide producer of ion implantation, dry strip, rapid thermal processing and photostabilization equipment used in the fabrication of semiconductors in the United States, Europe and Asia. In addition, the Company provides extensive aftermarket service and support, including spare parts, equipment upgrades, maintenance services and customer training. The Company owns 50% of the equity of a joint venture with Sumitomo Heavy Industries, Ltd. in Japan. This joint venture, which is known as Sumitomo Eaton Nova Corporation, or SEN, licenses technology from the Company relating to the manufacture of ion implantation products and has exclusive rights to manufacture and sell these products to the territory of Japan. SEN is the leading producer of ion implantation equipment in Japan.

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments which are of a normal recurring nature, except for adjustments to record a valuation allowance for deferred tax assets (see Note 7) and reflect a change in estimate relating to unfunded pension liabilities and other benefit claims (see Note 8), considered necessary for a fair presentation have been included. Operating results for the three and six month periods ended June 30, 2003 are not necessarily indicative of the results that may be expected for other interim periods or for the year ended December 31, 2003.

The balance sheet at December 31, 2002 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

For further information, refer to the consolidated financial statements and footnotes thereto included in Axcelis Technologies, Inc.'s annual report on Form 10-K for the year ended December 31, 2002.

2)     Net Income (Loss) Per Share

Basic net income (loss) per share is calculated based on the weighted average shares of common stock outstanding during the period. Diluted net income per share is calculated based on the weighted average shares of common stock outstanding, plus the dilutive effect of stock options, calculated using the treasury stock method, and the assumed conversion of convertible debt using the if converted method, when antidilutive.

3)      Comprehensive Income (Loss)
The components of comprehensive income (loss) are as follows (in thousands):

	Three Months Ended						Six Months Ended
	June 30,			June 30,			June 30,			June 30,
	2003			2002			2003			2002
Net loss	$	(78,878	)	$	(1,677	)	$	(85,204	)	$	(19,508	)
Foreign currency translation adjustments		803			9,215			1,199			8,347
Comprehensive income (loss)		(78,075	)		7,538			(84,005	)		(11,161	)

4)      Inventories
Inventories are carried at the lower of cost, determined using the first-in, first out (FIFO) method, or market. The components of inventory were as follows (in thousands):

	June 30,			December 31,
	2003			2002
Raw materials	$	78,515		$	80,642
Work-in-process		2,271			13,401
Finished goods		44,512			35,939
		125,298			129,982
Inventory allowances		(14,874	)		(14,692	)
	$	110,424		$	115,290

5)      Product Warranty and Installation Costs

The Company offers a one to three year warranty for all of its products, the terms and conditions of which vary depending upon the product sold. The Company estimates the costs that may be incurred under its warranty and product installation obligation and records a liability in the amount of such costs at the time product revenue is recognized. Factors that affect the Company's warranty and installation liability include the number of installed units, historical and anticipated product failure rates, material usage and service labor costs. The Company periodically assesses the adequacy of its recorded warranty and installation liability and adjusts the amount as necessary.

Changes in the Company's product warranty and installation liability for the period ended June 30, 2003 are as follows (in thousands):

Balance at December 31, 2002	$	16,625
Warranties and installations issued during the period		12,875
Settlements made during the period		(12,949	)
Changes in liability for pre-existing warranties and installation during the period		(1,603	)
Balance as of June 30, 2003	$	14,948

6)      Stock-Based Compensation

As permitted under Statement of Financial Accounting Standards (SFAS) No. 123, "Accounting for Stock-Based Compensation," as amended by SFAS No. 148 "Accounting for Stock-Based Compensation Transition and Disclosure," Axcelis has elected to follow Accounting Principles Board (APB) No. 25 in accounting for stock-based awards to employees. Under APB No. 25, the Company recognizes no compensation expense with respect to such awards, if on the date the awards were granted, the exercise price equaled the market value of the common shares.

Pro forma information regarding net income (loss) is required by SFAS No. 123. This information is required to be determined as if Axcelis had accounted for stock-based awards to its employees granted subsequent to 1995 under the fair value method prescribed by SFAS No. 123. The fair values of the options granted have been estimated at the date of grant using the Black-Scholes options pricing model.

The Black-Scholes options valuation model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions, including the expected stock price volatility. Because Axcelis' options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in the opinion of management, the existing models do not necessarily provide a reliable single measure of the fair value of the Company's options.

For purposes of pro forma disclosures under SFAS No. 123, the estimated fair values of the options are assumed to be amortized to expense over the options' vesting periods. Pro forma information related to options granted follows (in thousands, except per share amounts):

	Three Months Ended						Six Months Ended
	June 30,			June 30,			June 30,			June 30,
	2003			2002			2003			2002
Net loss	$	(78,878	)	$	(1,677	)	$	(85,204	)	$	(19,508	)
Deduct: Total stock-based employee compensation expense determined under fair value based method for all awards, net of related tax effects		(4,311	)		(4,554	)		(7,234	)		(9,084	)
Proforma net loss		(83,189	)		(6,231	)		(92,438	)		(28,592	)
Net loss per share
Basic - as reported	$	(0.80	)	$	(0.02	)	$	(0.87	)	$	(0.20	)
Basic - pro forma	$	(0.85	)	$	(0.06	)	$	(0.94	)	$	(0.29	)
Diluted - as reported	$	(0.80	)	$	(0.02	)	$	(0.87	)	$	(0.20	)
Diluted - pro forma	$	(0.85	)	$	(0.06	)	$	(0.94	)	$	(0.29	)

7)      Deferred Income Taxes

The Company has deferred tax assets resulting from tax credit carryforwards, net operating losses and other deductible temporary differences, which are available to reduce taxable income in future periods. SFAS No. 109 "Accounting for Income Taxes" requires that a valuation allowance be established when it is "more likely than not" that all or a portion of deferred tax assets will not be realized. A review of all available positive and negative evidence needs to be considered, including a company's performance, the market environment in which the Company operates, length of carryback and carryforward periods, existing sales backlog and projections of future operating results. Where there are cumulative losses in recent years, SFAS No. 109 creates a strong presumption that a valuation allowance is needed. This presumption can be overcome in very limited circumstances.

As of March 31, 2003, the Company's evaluation of the realization of these assets was based upon evidence of cumulative historical profitability and estimates of future taxable income. The Company was profitable in fiscal year 2000 but was not profitable in fiscal years 2001 and 2002. Projections of future earnings were based on revenue assumptions consistent with industry forecasts for the next three years along with the necessary operating expenses to support the Company's revenue assumptions. Based on these projections, the Company estimated that the loss carryforwards would be fully utilized within three years.

During the second quarter of 2003, the Company entered a three year cumulative loss position and revised its projections of the amount and timing of future earnings. Due to these factors as well as the uncertainty of the amount and timing of profitability in future periods, the Company increased its valuation allowance as of June 30, 2003. This non-cash charge to earnings increased income tax expense by $69.7 million for the three and six month periods ended June 30, 2003.

The Company expects to record a full valuation allowance on future tax benefits until it can sustain an appropriate level of profitability and until such time, the Company would not expect to recognize any significant tax benefits in its future results of operations. However, going forward should the Company return to profitability and there is sufficient evidence, in accordance with the provisions of SFAS No. 109, to support the ultimate realization of income tax benefits attributable to net operating losses, tax credit carryforwards and other deductible temporary differences, the carrying value of deferred tax assets may be restored, resulting in a non-cash credit to earnings.

8)      General and Administrative Expenses

General and administrative expenses for the three and six month periods ended June 30, 2003 have been reduced by $1.7 million, representing an adjustment to reflect a change in estimate relating to an overaccrual for unfunded pension liabilities and other benefit claims recorded in prior periods.

9)      Recent Accounting Pronouncements

In January 2003, the FASB issued Interpretation No. 46 "Consolidation of Variable Interest Entities, an Interpretation of Accounting Research Bulletin No. 51" (FIN 46). FIN 46 provides a new consolidation model which determines control and consolidation based on potential variability in gains and losses. The provisions of FIN 46 are effective for enterprises with variable interests in variable interest entities created after January 31, 2003. For public companies with variable interest in variable interest entities created before February 1, 2003, the provisions of FIN 46 are to be applied no later than July 1, 2003. The Company is currently assessing whether its equity investment in SEN constitutes a variable interest entity that would require consolidation of SEN beginning with the third quarter of 2003.

In November 2002, the Emerging Issues Task Force (EITF) of the FASB reached a consensus on EITF No. 00-21, Accounting for Revenue Arrangements with Multiple Element Deliverables. The Issue addresses how to account for arrangements that may involve the delivery or performance of multiple products, services and/or rights to use assets. Revenue arrangements with multiple deliverables should be divided into separate units of accounting if the deliverables in the arrangement meet certain criteria. Arrangement consideration should be allocated among the separate units of accounting based on their relative fair values. The Issue also supersedes certain guidance set forth in SAB 101. The final consensus is applicable for revenue arrangements entered into in fiscal periods beginning after June 15, 2003. The Company is currently evaluating the impact the provision of EITF 00-21 may have on its financial statements.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Certain statements in "Management's Discussion and Analysis of Financial Condition and Results of Operations" are forward-looking statements that involve risks and uncertainties. Words such as may, will, should, would, anticipates, expects, intends, plans, believes, seeks, estimates and similar expressions identify such forward-looking statements. The forward-looking statements contained herein are based on current expectations and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Factors that might cause such a difference include, among other things, those set forth under "Financial Condition, Liquidity and Capital Resources" and "Risk Factors" included in these sections and those appearing elsewhere in this Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The Company assumes no obligation to update these forward-looking statements to reflect actual results or changes in factors or assumptions affecting forward-looking statements.

Overview

We are a worldwide producer of ion implantation, dry strip, rapid thermal processing and photostabilization equipment used in the fabrication of semiconductors. In addition, we provide extensive aftermarket service and support, including spare parts, equipment upgrades, maintenance services and customer training. We own 50% of the equity of a joint venture with Sumitomo Heavy Industries, Ltd. in Japan. This joint venture licenses technology from the Company relating to the manufacture of ion implantation products and has exclusive rights to manufacture and sell these products to the territory of Japan. SEN is the leading producer of ion implantation equipment in Japan.

Critical Accounting Policies

Management's discussion and analysis of our financial condition and results of operations are based upon Axcelis' consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, including those related to revenue recognition, income taxes, accounts receivable, inventory and warranty and installation obligations. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

The Company believes the following accounting policies are critical in the portrayal of our financial condition and results of operations and require management's most significant judgments and estimates in the preparation of our consolidated financial statements.

Revenue Recognition

The Company's revenue recognition policy involves significant judgment by management. As described in detail below, the Company considers a broad array of facts and circumstances in determining when to recognize revenue, including the complexity of the customer's post delivery acceptance provisions and the installation process. In the future, if the post delivery acceptance provisions and installation process become more complex or result in a materially lower rate of acceptance than we now experience, the Company may have to revise its revenue recognition policy, which could affect the timing of revenue recognition.

Axcelis generally recognizes the full sale price at the time of shipment to the customer. The costs of system installation at the customer's site are accrued at the time of shipment. Customer payment terms typically provide that the majority of the purchase price is paid upon shipment, but these terms also contain delayed payment arrangements for a portion of the purchase price, which are primarily time-based. In addition, the Company incurs installation and acceptance testing performance obligations at the time of sale.

Management believes the customer's post delivery acceptance provisions and installation process have been established to be routine, commercially inconsequential and perfunctory because the process is a replication of the pre-shipment procedures. The majority of Axcelis' systems are designed and tailored to meet the customer's specifications as outlined in the contract between the customer and Axcelis. To ensure that the customer's specifications are satisfied, per contract terms, the majority of customers request that the systems are to be tested at Axcelis' facilities prior to shipment, normally with the customer present, under conditions that substantially replicate the customer's production environment and the customer's criteria are confirmed to have been met. Customers for mature products generally do not require pre-shipment testing. Axcelis has never failed to successfully complete a system installation. Should an installation not be successfully completed, the contractual provisions do not provide for forfeiture, refund or other purchase price concession beyond those prescribed by the provisions of the Uniform Commercial Code applicable generally to such transactions. Installation is non-complex and does not require specialized skills, and the related costs are predictable and insignificant to the total purchase price. Axcelis has a demonstrated history of customer acceptance subsequent to shipment and installation of these systems.

In the small number of instances where Axcelis is unsure of meeting the customer's specifications upon shipment of the system, Axcelis will defer the recognition of revenue until written customer acceptance of the system. This deferral period is generally within twelve months of shipment.

Deferred Tax Assets

The Company has deferred tax assets resulting from tax credit carryforwards, net operating losses and other deductible temporary differences, which are available to reduce taxable income in future periods. SFAS No. 109 "Accounting for Income Taxes" requires that a valuation allowance be established when it is "more likely than not" that all or a portion of deferred tax assets will not be realized. A review of all available positive and negative evidence needs to be considered, including a company's performance, the market environment in which the Company operates, length of carryback and carryforward periods, existing sales backlog and projections of future operating results. Where there are cumulative losses in recent years, SFAS No. 109 creates a strong presumption that a valuation allowance is needed. This presumption can be overcome in very limited circumstances.

As of March 31, 2003, the Company's evaluation of the realization of these assets was based upon evidence of cumulative historical profitability and estimates of future taxable income. The Company was profitable in fiscal year 2000 but was not profitable in fiscal years 2001 and 2002. Projections of future earnings were based on revenue assumptions consistent with industry forecasts for the next three years along with the necessary operating expenses to support the Company's revenue assumptions. Based on these projections, the Company estimated that the loss carryforwards would be fully utilized within three years.

During the second quarter of 2003, the Company entered a three year cumulative loss position and revised its projections of the amount and timing of future earnings. Due to these factors as well as the uncertainty of the amount and timing of profitability in future periods, the Company increased its valuation allowance as of June 30, 2003. This non-cash charge to earnings increased income tax expense by $69.7 million for the three and six month periods ended June 30, 2003.

The Company expects to record a full valuation allowance on future tax benefits until it can sustain an appropriate level of profitability and until such time, the Company would not expect to recognize any significant tax benefits in its future results of operations. However, going forward should the Company return to profitability and there is sufficient evidence, in accordance with the provisions of SFAS No. 109, to support the ultimate realization of income tax benefits attributable to net operating losses, tax credit carryforwards and other deductible temporary differences, the carrying value of deferred tax assets may be restored, resulting in a non-cash credit to earnings.

Goodwill and Other Intangible Assets

We account for our acquisitions under the purchase method of accounting pursuant to Statement of Financial Accounting Standard (SFAS) No. 141, "Business Combinations". Goodwill represents the excess of cost over net assets, including all identifiable intangible assets of acquired businesses that are consolidated. Pursuant to SFAS No. 142, "Goodwill and Other Intangible Assets," goodwill is not amortized. Other intangible assets that are separable from goodwill and have determinable useful lives are valued separately and amortized over their useful lives. Such other identifiable intangible assets consist mainly of developed technology and are generally amortized over approximately ten years. We have determined that all of our intangible assets have finite lives.

During 2002, in accordance with SFAS No. 142, we ceased to amortize goodwill arising primarily from our 1997 acquisition of our dry strip and photostabilization businesses. In lieu of amortization, we perform an impairment review of our goodwill. Impairment tests are performed annually, or more frequently if there are other indicators of impairment. The annual impairment test consists of determining the fair market value of the business unit through a discounted cash flow analysis. Management's best judgments are employed in determining future market conditions that impact this discounted cash flow analysis. As a result of our annual review, we determined that there was no impairment of our goodwill. If we determine through the impairment review process that goodwill has been impaired, we would record the impairment charge in our statement of operations as a non-cash charge to earnings. Net goodwill amounted to $40.7 million as of June 30, 2003.

We assess the impairment of identifiable other intangible assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors we consider important that could trigger an impairment review include the following:

    •  a significant underperformance relative to expected historical or projected future operating results;

    •  a significant change in the manner of our use of the acquired asset or the strategy for our overall business;

    •  a significant negative industry or economic trend; and

    •  our market capitalization relative to net book value.

As part of this assessment, we would review the expected future undiscounted cash flows to be generated by the assets. When we determine that the carrying value of intangibles may not be recoverable, we measure any impairment based on a projected discounted cash flow method using a discount rate determined by our management to be commensurate with the risk inherent in our current business model. Net intangible assets, other than goodwill, amounted to $12.4 million as of June 30, 2003.

Accounts Receivable

Axcelis records an allowance for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. If the financial condition of Axcelis' customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be necessary. The allowance for doubtful accounts amounted to $3.5 million as of June 30, 2003.

Inventories

Axcelis records an allowance for estimated excess and obsolete inventory. The allowance is based upon management's assumptions of future materials usage and obsolescence, based on estimates of future demand and market conditions. If actual market conditions become less favorable than those projected by management, additional inventory write-downs may be required. The allowance for excess and obsolete inventory amounted to $14.9 million as of June 30, 2003.

Product Warranty and Installation Costs

Axcelis provides for the estimated cost of product warranties and installations at the time of shipment. The Company's warranty and installation obligation is affected by product failure rates, material usage and service labor costs incurred in correcting a product failure or installing a system at a customer's site. If actual product failure rates, material usage or service labor costs differ from management's estimates, revisions to the estimated warranty and installation liability may be required. The company's estimated warranty and installation liability was $14.9 million as of June 30, 2003.

Results of Operations

The following table sets forth consolidated statements of operations data expressed as a percentage of net sales for the periods indicated:

		Three Months Ended						Six Months Ended
		June 30,			June 30,			June 30,			June 30,
		2003			2002			2003			2002
Net sales			100.0	%		100.0	%		100.0	%		100.0	%
Gross profit			31.9			37.3			32.7			32.2
Other costs and expenses:
	Research and development		18.8			20.9			19.2			24.0
	Selling		13.6			13.2			14.1			15.2
	General and administrative		10.8			13.1			11.7			15.6
	Amortization of intangible assets		0.4			0.4			0.4			0.5
Loss from operations			(11.7	)		(10.3	)		(12.7	)		(23.2	)
Other income (expense):
	Royalty income		1.5			3.8			1.8			2.6
	Equity income of SEN		1.5			3.7			2.7			0.9
	Interest income		0.6			1.2			0.6			1.3
	Interest expense		(1.6	)		(1.9	)		(1.7	)		(1.9	)
	Other-net		(0.9	)		(1.4	)		(0.6	)		(1.1	)
Loss before income taxes			(10.6	)		(5.0	)		(9.9	)		(21.4	)
Income taxes (credit)			82.6			(3.1	)		41.1	)		(8.5	)
Net loss			(93.2	)%		(1.9	)%		(51.0	)%		(12.9	)%

Net Sales

Net sales for the second quarter of fiscal 2003 were $84.7 million, a decrease of $4.3 million, or 4.9%, from $89.0 million in the second quarter of 2002. Net sales for the six months ended June 30, 2003 were $167.1 million, an increase of $16.0 million, or 10.6%, from $151.1 million for the same period in fiscal 2002. The changes in net sales from comparable periods in 2002 were primarily attributable to the timing of orders received from and related shipments of products to our semiconductor manufacturing customers. The Company does not believe the changes in sales volumes during the three and six month periods ended June 30, 2003, reflect any significant changes in the levels of capital spending within the semiconductor manufacturing industry.

Gross Profit

Gross profit for the second quarter of fiscal 2003 was $27.0 million, a decrease of $6.2 million, or 18.7%, from $33.2 million in the second quarter of fiscal 2002. Gross profit for the six months ended June 30, 2003 was $54.7 million, an increase of $6.1 million, or 12.5%, from $48.6 million for the same period in fiscal 2002. Fluctuation in gross margins in terms of absolute dollars are the resultant effect of changes in sales volume, combined with changes in gross profit percentage.

Gross profit as a percentage of net sales decreased to 31.9% in the second quarter of fiscal 2003 from 37.3% in the comparable prior period. The decrease in gross profit percentage during the second quarter is related principally to reduced selling prices caused by a competitive market environment. For the first half of fiscal 2003, gross profit as a percentage of net sales increased to 32.7% from 32.2% from the first half of fiscal 2002. For the six month period, the pricing pressure reflected by the competitive market environment was offset by increased manufacturing capacity utilization caused by higher sales volume and an increasing mix of higher margin 200mm equipment sales. Sales of 200mm products constituted approximately 68.6% of systems sales in the first half of 2003 compared to 53.7% in the comparable period of 2002.

Operating Expenses

Operating expenses were 43.6% of net sales for the three months ended June 30, 2003, compared to 47.6% for the three months ended June 30, 2002, reflecting a decrease in spending of $5.4 million comprising a decrease of $2.6 million in research and development expenses and a decrease of $2.8 million in selling, general and administrative expenses. Operating expenses were 45.5% of net sales for the six months ended June 30, 2003, compared to 55.4% for the six months ended June 30, 2002, reflecting a decrease in spending of $7.6 million comprising a decrease of $4.1 million in research and development expenses and a decrease of $3.5 million in selling, general and adminstrative expenses. For both the three and six month periods ended June 30, 2003 the decrease in research and development costs was due principally to the completion and release of all 300mm products in the second half of 2002 and the associated reduction in headcount-related and material costs. The decreases in selling, general and administrative expenses are attributable to lower costs associated with programmed headcount reductions and an adjustment of $1.7 million recorded in the second quarter to reflect a change in estimate relating to unfunded pension expense and other benefit claims recorded in prior periods.

Income (Loss) From Operations

Loss from operations was $9.9 million for the second quarter of fiscal 2003 as compared to a loss of $9.1 million for the second quarter of fiscal 2002. Loss from operations was $21.3 million for the six months ended June 30, 2003 as compared to a loss of $35.0 million for the six months ended June 30, 2002. The decreases were primarily a result of the factors described above.

Other Income (Expense)

Other income, net, decreased to $0.9 million for the second quarter of fiscal 2003 as compared to $4.8 million for the second quarter of fiscal 2002. Other income, net, increased to $4.8 million for the first half of fiscal 2003 from $2.7 million for the first half of 2002. Total other income consists primarily of royalty income and equity income from SEN. Royalty income from SEN was $1.2 million and $3.0 million for the three and six month periods ended June 30, 2003, respectively, compared to $3.4 million and $3.9 million for the corresponding periods of 2002. Changes in royalty and equity contributions from SEN reflect increases or decreases in its sales volume and operating earnings resulting from changes in the Japanese semiconductor market. The Company does not believe the changes in sales volume during the three and six month periods ended June 30, 2003 reflect any significant changes in the level of capital spending within the Japanese semiconductor manufacturing industry.

Interest expense relates to the Company's $125 million convertible subordinated note offering completed in January 2002.

Income Taxes (Credit)

Income taxes for the three and six month periods ended June 30, 2003 consist primarily of a valuation allowance of $69.7 million recorded at June 30, 2003 to reduce the carrying value of deferred tax assets to zero. Income tax benefits for the three and six month periods ended June 30, 2002 were recorded at the Company's estimated annual effective tax rate.

Net Income (Loss)

The Company incurred a net loss of $78.9 million in the second quarter of fiscal 2003 as compared to a net loss of $1.7 million in the second quarter of fiscal 2002. The increase was principally a result of the factors discussed above. Our loss per share (basic and diluted) was $0.80 in the second quarter of fiscal 2003 and $0.87 in the first half of fiscal 2003. Our loss per share (basic and diluted) was $0.02 in the second quarter of 2002 and $0.20 in the first half of fiscal 2002.

Financial Condition, Liquidity and Capital Resources

As of June 30, 2003, cash and cash equivalents were $116.6 million as compared with $150.7 million as of December 31, 2002. Short-term investments were $36.9 million as of June 30, 2003 compared to $35.0 million at December 31, 2002. The decrease in the combined amount of cash, cash equivalents and short-term investments from December 31, 2002 resulted principally from operating losses and increases in accounts receivable reflecting increased sales volume during the six month period ended June 30, 2003.

Net working capital was $264.0 million at June 30, 2003 as compared to net working capital of $292.4 million at December 31, 2002. The reduction in working capital is attributable principally to the loss before income taxes and the recognition of a valuation allowance relating to the current portion of deferred tax assets.

Net cash used by operating activities was $30.7 million for the six months ended June 30, 2003 as compared to net cash used by operating activities of $29.8 million for the six months ended June 30, 2002.

Capital expenditures were $2.2 million in the first six months of fiscal 2003 and $8.9 million in the first six months of fiscal 2002. The decrease in capital expenditures in the first half of fiscal 2003 was principally due to the completion of the Company's addition to its Beverly, Massachusetts facility during the first half of fiscal 2002. The amount of future capital requirements will depend on a number of factors, including the timing and rate of the expansion of our business.

On July 3, 2003, the Company completed the acquisition of Matrix Integrated Systems, Inc., a photoresist dry strip equipment supplier based in Richmond, California for $14 million in cash. This acquisition expands and strengthens Axcelis' dry strip technology portfolio, but the impact of the acquisition is not material to the Company as a whole.

Axcelis' liquidity is affected by many factors. Some of these factors are based on normal operations of the business and others relate to the uncertainties of global economies and the semiconductor equipment industry. As a general rule, we would expect to consume cash at the beginning of a cyclical upturn and generate cash at the beginning of a cyclical downturn, due primarily to changes in working capital requirements. Although our cash requirements fluctuate based on the timing and the extent of these factors, we believe that available cash and our cash flows from operations will provide sufficient working capital and satisfy commitments for capital expenditures and other cash requirements of the business.

Outlook

The Company's performance for the three and six month periods ended June 30, 2003 was directly related to the continuing low levels of capital expenditures by semiconductor manufacturers, especially manufacturers opening new or expanding existing fabrication facilities. The level of capital expenditures by these manufacturers depends upon the current and anticipated market demand for semiconductors and the products utilizing them, the available manufacturing capacity in manufacturers' fabrication facilities, and the ability of manufacturers to increase productivity in existing facilities without incurring additional capital expenditures. Currently, management along with industry and economic analysts believe that semiconductor manufacturers are looking to expand capacity and increase capital spending over the next twelve to twenty-four months. The Company does not believe it will realize any benefit in terms of increased revenues and improved operating performance from this anticipated upturn in capital spending before the fourth quarter of 2003 at the earliest.

Also during the first half of 2003, the Company experienced increasing competitive pricing pressure at strategic accounts, and management expects that this pressure will continue for the remainder of 2003 as buying remains concentrated among fewer customers. In the second quarter of 2003, the Company's top five customers represented 77% of system revenues.

In reaction to the continued low sales volume and the pricing pressure, management has continued its ongoing actions to reduce manufacturing costs as well as decrease research and development and SG&A expense.

On July 29, 2003, the Company announced its expectation that its revenues for the third quarter of fiscal 2003 will be in the range of $60 to $70 million, a decrease of 17% to 29% in comparison to the reported revenues for the second quarter of 2003. On these forecast revenues, management stated on July 29, 2003 that gross margins are expected to be in the low 30% range and the net loss for the third quarter of fiscal 2003 is expected to be $0.16 to $0.18 per share. Management is continuing to manage the Company's cost structure on a quarterly basis with the objective of returning to profitability, while at the same time making sure that the Company has the right resources for an upturn in demand for its systems.

It is difficult for management to predict customers' capital spending plans, which can change very quickly. In addition, at the current sales level, each sale, or failure to make a sale, could have a material effect on the Company in a particular quarter.

Risk Factors

As defined under Safe Harbor provisions of The Private Securities Litigation Reform Act of 1995, some of the matters discussed in this filing contain forward-looking statements regarding future events that are subject to risks and uncertainties. The following factors, among others, could cause actual results to differ materially from those described by such statements. These factors include, but are not limited to: the cyclical nature of the semiconductor industry, our ability to keep pace with rapid technological changes in semiconductor manufacturing processes, the highly competitive nature of the semiconductor equipment industry, quarterly fluctuations in operating results attributable to the timing and amount of orders for our products and services, dependency on SEN (our Japanese joint venture) for access to the Japanese semiconductor equipment market, and those risk factors contained in the section titled "Outlook" and Exhibit 99.1 of this Form 10-Q. If any of those risk factors actually occur, our business, financial condition and results of operations could be seriously harmed and the trading price of our common stock could decline.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

A discussion of market risk exposures is included in our Form 10-K for the year ended December 31, 2002 under Management's Discussion and Analysis - Outlook and Exhibit 99.1 filed herewith.

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures.

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this quarterly report. Based on this evaluation, our principal executive officer and principal financial officer concluded that these disclosure controls and procedures are effective and designed to ensure that the information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the requisite time periods.

(b) Changes in Internal Controls.

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) identified in connection with the evaluation of our internal control performed during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

On January 8, 2001, we filed a lawsuit against Applied Materials, Inc. ("Applied") in the United States District Court for the District of Massachusetts. The complaint alleges that Applied's medium current/high energy ion implanter machine launched in November 2000 infringes our patent for ion implantation equipment using radio frequency linear accelerator technology. We have also alleged that Applied unlawfully interfered with our existing and future contracts. On January 18, 2001, we filed a motion for a preliminary injunction for the reason, among others, that infringement at the time of transition between equipment capable of handling 200 mm wafers and equipment capable of handling 300 mm wafers would irreparably harm us. Through this motion, we asked the court to stop Applied from manufacturing, selling or offering to sell its medium current/high energy ion implanter machine and to order Applied to remove all Axcelis patented technology from implanters that Applied may have placed in chipmakers' plants for process development trials. Applied filed counterclaims of unfair competition, defamation, and tortious interference with prospective economic advantage, all of which it contends arise from certain communications allegedly made by Axcelis about the lawsuit and its claims of infringement.

A jury trial on the sole issue of infringement commenced on June 16, 2003. On July 2, 2003, the jury issued a verdict in favor of Applied Materials. The Company is planning to file a notice of appeal in August 2003. While there can be no assurance of a favorable outcome from an appeal, we continue to believe our claims are meritorious. We expect the requisite investment in legal expense to pursue an appeal will be minimal. We do not believe that our pursuit of this matter will have a material adverse effect on our financial condition, results of operations or liquidity. The patent at issue expires in mid 2005.

Item 4. Submission of Matters to a Vote of Security Holders

The Annual Meeting of Stockholders of Axcelis Technologies, Inc. was held at the offices of Palmer & Dodge, LLP, 111 Huntington Avenue, Boston Massachusetts on June 26, 2003. Out of 98,395,258 shares of Common Stock (as of the record date of April 28, 2003) entitled to vote at the meeting, 89,103,118 shares, or 90.5%, were present in person or by proxy.

(a) Election of Directors. Each of the three directors nominated for election at the Annual Meeting was elected by a plurality of votes cast, to serve for a three year term ending in 2006, and until their successors are elected. The vote was as follows:

	Number of Votes
	For		Withheld
Mary G. Puma		87,977,234		1,152,884
Naoki Takahashi		87,994,369		1,135,749
William C. Jennings		88,628,266		501,852

(b) Ratification of Appointment of Auditors. A majority of the securities present, or represented, and entitled to vote at the meeting voted in favor of the proposal to ratify the appointment by the Board of Directors of Ernst & Young LLP as independent auditors of the Company's financial statements for the year ending December 31, 2003. The following sets forth the tally of the votes cast on the proposal:

Number of Votes
For	Against	Abstaining	Percentage For
86,005,693	3,012,508	111,917	96.49%

Item 5. Other Information

On July 3, 2003, the Company completed the acquisition of Matrix Integrated Systems, Inc., a photoresist dry strip equipment supplier based in Richmond, California for $14 million in cash. This acquisition expands and strengthens Axcelis' dry strip technology portfolio, but the impact of the acquisition is not material to the Company as a whole.

Item 6. Exhibits and Reports on Form 8-K

a) Exhibits are numbered in accordance with the Exhibit Table of Item 601 of Regulation S-K:

Exhibit No.	Description
3.1	Amended and Restated Certificate of Incorporation of the Company. Incorporated by reference from Exhibit 3.1 of the Company's Registration Statement on Form S-1 (Registration No. 333-36330).
3.2	Bylaws of the Company, as amended as of January 23, 2002. Incorporated by reference from Exhibit 3.2 of the Company's Form 10-K for the year ended December 31, 2001, filed with the Commission on March 12, 2002.
3.3	Certificate of Designation of Series A Participating Preferred Stock, filed with the Secretary of State of Delaware on July 5, 2000. Incorporated by reference from Exhibit 3.3 of the Company's Form 10-K for the year ended December 31, 2000, filed with the Commission on March 30, 2001.
10.10*	Consulting Agreement between the Company and Stephen G. Bassett, dated June 9, 2003. Filed herewith.
31.1	Certification of the Chief Executive Officer under Exchange Act Rule 13a-14(a)/15d-14(a) (Section 302 of the Sarbanes-Oxley Act), dated August 13, 2003. Filed herewith.
31.2	Certification of the Chief Financial Officer under Exchange Act Rule 13a-14(a)/15d-14(a) (Section 302 of the Sarbanes-Oxley Act), dated August 13, 2003. Filed herewith.
32.1	Certification of the Chief Executive Officer pursuant to Section 1350 of Chapter 63 of title 18 of the United States Code (Section 906 of the Sarbanes-Oxley Act), dated August 13, 2003. Filed herewith.
32.2	Certification of the Chief Financial Officer pursuant to Section 1350 of Chapter 63 of title 18 of the United States Code (Section 906 of the Sarbanes-Oxley Act), dated August 13, 2003. Filed herewith.
99.1	Factors Affecting Future Operating Results for the Form 10-Q for the period ended June 30, 2003. Filed herewith.

*   Indicates a management contract or compensatory plan.

b) Reports on Form 8-K

   (i) A Current Report on Form 8-K dated May 1, 2003, was filed with the Securities and Exchange Commission on May 6, 2003 relating to the Company's announcement of earnings for its quarter ended March 30, 2003.

   (ii) A Current Report on Form 8-K dated June 9, 2003, was filed with the Securities and Exchange Commission on June 10, 2003 relating to the resignation of Cornelius F. Moses, the Company's former chief financial officer.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AXCELIS TECHNOLOGIES, INC.

Dated:   August 13, 2003

By:  /s/ Stephen G. Bassett

Stephen G. Bassett

Chief Financial Officer
Duly authorized officer and
Principal financial officer

EX-10 3 ex10_10.txt S. BASSETT CONSULTING AGREEMENT Exhibit 10.10 AXCELIS TECHNOLOGIES, INC. INDEPENDENT CONSULTANT AGREEMENT This Agreement is entered into effective this 9th day of June, 2003 by and between Axcelis Technologies, Inc., a Delaware corporation with its principal office at 55 Cherry Hill Drive, Beverly, Massachusetts 01915 ("Axcelis") and Stephen G. Bassett, with an address at 2 Keystone Way, Andover, Massachusetts ("Consultant"). In consideration of the mutual covenants and promises contained herein, Axcelis and Consultant agree as follows: 1. Performance of Services. Consultant agrees to provide to Axcelis the services generally described in Schedule 1 (the "Services"). Consultant shall supply all necessary supplies and materials and shall be solely responsible for requesting any information necessary from Axcelis for the performance of the Services. Consultant shall not employ any subcontractors for any of the Services without the prior written approval of Axcelis, and Consultant shall remain responsible for the performance of any such subcontractors. Consultant shall perform the Services in accordance with the professional standards of skill, care, and diligence. 2. Time. Consultant agrees to adhere to the time commitments set forth in Schedule 1 or as otherwise mutually agreed upon. Consultant shall perform the Services as expeditiously as is consistent with the standards of professional skill and care required hereby. Consultant shall perform the Services in coordination with the operations of Axcelis and with any party engaged by Axcelis in connection with the Services being performed. 3. Payment. 3.1. Fees. For the Services provided by Consultant under this Agreement, Axcelis agrees to compensate Consultant according to Schedule 2. 3.2. Reimbursable Expenses. Axcelis shall compensate Consultant for reasonable expenses actually incurred by Consultant to the extent provided in Schedule 1 ("Reimbursable Expenses"). Consultant agrees that if such expenses are for travel, Consultant shall either (i) use Axcelis' travel partner or (ii) limit its travel expenses such that Consultant's expenses do not exceed those quoted by Axcelis' travel partner (as per the Axcelis Travel Policy for Independent Contractors and Temporary Workers). Consultant agrees to use reasonable efforts to minimize Reimbursable Expenses. 4. [Intentionally Omitted] 5. Inventions. 5.1. Definition and Disclosure. As used in this Agreement, "Inventions" shall mean any and all ideas, concepts, discoveries, inventions, developments, trade secrets, methods, data, information, improvements, materials, Work Product (as defined in Section 5.4 below), and know-how that are conceived, devised, invented, developed or reduced to practice or tangible medium (whether or not protectible under state, federal or foreign patent, copyright, trade secrecy or similar laws), by Consultant, under Consultant's direction or jointly with others during any period that Consultant is engaged by Axcelis, which relate, directly or indirectly, to the business of Axcelis and arise out of Consultant's performance of this Agreement. Consultant agrees promptly to disclose all Inventions to Axcelis. 5.2. Assignment of Rights. Consultant covenants and agrees that all right, title and interest in any Inventions shall remain the sole and exclusive property of Corporation and shall be a work made for hire. Consultant hereby assigns and agrees to assign to Axcelis all of Consultant's right, title and interest in and to the Inventions and any and all related patent rights, copyrights, and other intellectual property rights and applications and registrations therefor. During and after Consultant's engagement by Axcelis, Consultant shall cooperate with Axcelis, at Axcelis' expense, in obtaining protection for the Inventions and Consultant shall execute all documents which Axcelis shall reasonably request in order to perfect Axcelis' rights in the Inventions. Consultant hereby appoints Axcelis as Consultant's attorney to execute and deliver any such documents on Consultant's behalf in the event Consultant should fail or refuse to do so within a reasonable period following Axcelis' request. 5.3. No Conflict. Consultant represents and warrants that the assignment of Inventions to Axcelis or Axcelis' use of such Inventions shall not violate the copyright, patent, trademark, trade secret, or other right of any person or entity and no additional permissions, clearances, assignments, or licenses are necessary in order for Axcelis to own, use, and commercialize the Work Product (as defined below) and other Inventions. 5.4. Work Product. Without limiting the generality of the foregoing, Consultant further agrees that all right, title, and interest in and to any works of authorship or copyrightable materials resulting from the performance of the Services under this Agreement and all copies thereof, in whatever media (the "Work Product") shall be in Axcelis and shall be "works made for hire" within the meaning of the Copyright Law of the United States and may be used by Axcelis (or such parties as Axcelis may designate) thereafter in such manner and for such purposes as Axcelis (or such parties as Axcelis may designate) may deem advisable, without further employment of or additional compensation to Consultant. To the extent that the Work Product does not qualify for work made for hire status, Consultant hereby assigns and agrees to assign the entire worldwide, perpetual copyright in and to the Work Product to Axcelis pursuant to Section 5.2. 6. Confidentiality. 6.1. Definition. Consultant understands that Axcelis continually obtains and develops valuable proprietary and confidential information concerning its scientific, technical, or business affairs (the "Confidential Information") which may become known to Consultant in connection with Consultant's engagement by Axcelis. By way of illustration, but not limitation, Confidential Information includes Inventions and may include trade secrets, technical information, know-how, research and development activities of Axcelis, product and marketing plans, customer and supplier information and information disclosed to Axcelis or to Consultant by third parties of a proprietary or confidential nature or under an obligation of confidence. Confidential Information may be contained in various media, including without limitation, patent applications, research data and observations, computer programs in object and/or source code, technical specifications, laboratory notebooks, supplier and customer lists, internal financial data and other documents and records of Axcelis. 6.2. Proprietary Rights. Consultant acknowledges that all Confidential Information, either in writing and labeled or identified as confidential or proprietary or identified orally prior to disclosure by Axcelis as confidential or proprietary, is and shall remain the exclusive property of Axcelis or the third party providing such information to Consultant or Axcelis. Consultant agrees that Consultant shall not, during the term of Consultant's engagement by Axcelis and thereafter, publish, disclose or otherwise make available to any third party, other than employees of Axcelis, any Confidential Information except as expressly authorized in writing by Axcelis. Consultant agrees that Consultant shall use such Confidential Information only in the performance of Consultant's duties for Axcelis and in accordance with any Axcelis policies with respect to the protection of Confidential Information. Consultant agrees not to use such Confidential Information for Consultant's own benefit or for the benefit of any other person or business entity. 6.3. Precautions. Consultant agrees to exercise all reasonable precautions to protect the integrity and confidentiality of Confidential Information in Consultant's possession and not to remove any materials containing Confidential Information from Axcelis' premises except to the extent necessary to Consultant's performance of the Services. Upon the termination of Consultant's engagement hereunder, or at any time upon Axcelis' request, Consultant shall return immediately to Axcelis any and all materials containing any Confidential Information then in Consultant's possession or under Consultant's control. 6.4. Exceptions. Confidential Information shall not include information which (a) is or becomes generally known within Axcelis' industry through no fault of Consultant; (b) was known to Consultant at the time it was disclosed as evidenced by Consultant's written records at the time of disclosure; (c) is lawfully and in good faith made available to Consultant by a third party who did not derive it from Axcelis and who imposes no obligation of confidence on Consultant; or (d) is required to be disclosed by law or by a governmental authority or by order of a court of competent jurisdiction, provided that such disclosure is subject to all applicable governmental or judicial protection available for like material and reasonable advance notice is given to Axcelis. 7. Exclusivity; Non-Solicitation. 7.1. Exclusivity and Non-Compete. Consultant shall not, during the term of this Agreement, and for a period of one (1) year thereafter, organize or serve in any capacity (whether as an officer, director, employee, consultant or otherwise) any person, firm, corporation or other entity which is in direct competition with Axcelis or which may otherwise give rise to a conflict of interest or appearance of a conflict of interest with Consultant's performance of the Services, without the prior written consent of Axcelis. 7.2. Non-Solicitation. Consultant agrees that during the term of this Agreement and for a period of one (1) year thereafter, Consultant shall not induce or attempt to induce any of Axcelis' employees or independent contractors to terminate their employment or contractual relationships with Axcelis, or solicit, divert or take away, or attempt to divert or take away the business or patronage of any of the clients, customers or accounts, or prospective clients, customers or accounts of Axcelis which were contracted, solicited or served by Axcelis during the period in which Consultant was performing the Services for Axcelis. 8. Third Party Agreements and Rights. 8.1. No Conflict with Other Contracts. Consultant represents that Consultant's performance under this Agreement does not and shall not breach any fiduciary or other duty or any covenant, agreement or understanding (including, without limitation, any agreement relating to assignment of inventions, proprietary information, knowledge or data) to which Consultant is a party or by the terms of which Consultant may be bound. 8.2. Third Party Proprietary Rights. Consultant understands and acknowledges that Axcelis does not desire to acquire from Consultant any trade secrets, know-how, or confidential information Consultant may have acquired from third parties. Consultant therefore agrees that Consultant will not improperly use or disclose any proprietary information or trade secrets of any person or entity with whom Consultant owes a duty to keep such information in confidence. 9. Termination of Agreement. 9.1. Term. This Agreement shall expire on September 5, 2003, unless expressly renewed by the parties. After such date, Consultant agrees to make his Services available to Axcelis on a month -to-month basis at Axcelis' option, unless Consultant gives Axcelis 30 days prior notice of Consultant's unavailability to continue to provide such Services. The date of September 5, 2003 or any later expiration date agreed to by the parties is referred to herein as the "Expiration Date." 9.2. By Axcelis. Axcelis may terminate this Agreement prior to the Expiration Date as follows: (a) without cause, on 30 days' prior written notice; or (b) immediately, by written notice to Consultant, if Consultant fails to perform or observe any of the terms, covenants, obligations or conditions of this Agreement. 9.3. By Consultant. Consultant may terminate this Agreement prior to its Expiration Date as follows: (a) without cause, on 30 days' prior written notice, or (b) upon 10 days written notice to Axcelis, if Axcelis fails to make payments required under Section 3 above and Schedule 2. 9.4. Effect of Termination. In the event of termination by Axcelis prior to the Expiration Date, without cause, Axcelis shall promptly make the payments set forth on Schedule 2 as if the Consultant provided Services through the Expiration Date. The Success Fee, as described on Schedule 2, shall be paid when due. In the event of termination, Consultant shall promptly deliver to Axcelis all equipment and supplies belonging to Axcelis and all documents, work papers, studies, calculations, computer programs, data, drawings, plans, specifications and other tangible work product or materials pertaining to the Inventions and/or the Services performed under this Agreement to the time of termination. Any termination of this Agreement shall not affect or impair the right of Axcelis to recover damages occasioned by any default of Consultant or to set off such damages against amounts otherwise owed to Consultant. Any termination of this Agreement shall not affect or impair the right of Consultant to recover any payment due under this Agreement. Sections 5, 6, and 7, this Section 9.4 and Section 10 shall continue in full force and effect not withstanding the expiration or termination of this Agreement for any reason. 10. Miscellaneous. 10.1. Full Power and Authority. Each party represents and warrants that it has full power and authority to undertake the obligations set forth in this Agreement and that it has not entered into any other agreements that would render it incapable of satisfactorily performing its obligations hereunder. 10.2. Compliance with Law. Consultant shall perform the Services hereunder in compliance with all applicable federal, state and municipal laws, regulations, codes, ordinances and orders, and any permit conditions in effect as of the time of such performance. 10.3. Consultant's Accounting Records. Consultant shall keep records pertaining to the Services performed and Reimbursable Expenses employing sound bookkeeping practices and in accordance with generally accepted accounting principles. All records pertaining to the Services performed and Reimbursable Expenses shall be available to Axcelis or its authorized representatives for review and audit during normal business hours upon reasonably prior written notice to Consultant. 10.4. Non-Assignable. The Services are personal to Consultant and Consultant shall not assign, sublicense, or transfer any of its obligations, responsibilities, rights or interests (including, without limitation, its right to receive any moneys due hereunder) under this Agreement without the written consent of Axcelis. The Services may not be assumed by or assigned by a trustee in bankruptcy. Any assignment, subletting, or transfer by Consultant in violation of this Section 10.4 shall be void and without force or effect. 10.5. Entire Agreement. This Agreement represents the entire and integrated agreement between Axcelis and Consultant with respect to the subject matter hereof and supersedes all prior negotiations, representations or agreements, either written or oral. This Agreement may be amended only by written instrument signed by both Axcelis and Consultant. 10.6. Limitation of Liability. No officer, director, member, employee, or other principal, agent or representative (whether disclosed or undisclosed) of Axcelis shall be personally liable to Consultant hereunder, for Axcelis' payment obligations or otherwise. Consultant hereby agrees to look solely to the assets of Axcelis for the satisfaction of any liability of Axcelis hereunder. In no event shall Axcelis be liable to Consultant for indirect, incidental, special, reliance, exemplary, or consequential damages. 10.7. No Inadvertent Waivers. No waiver of any portion of this Agreement shall be effective unless in writing. The failure of Axcelis at any time to require performance by Consultant of any provision shall in no way affect the right of Axcelis to enforce that or any other provision of this Agreement. No waiver of any breach of this Agreement shall constitute a waiver of any subsequent breach of the same or any other provision of this Agreement. 10.8. Governing Law. This Agreement and the rights and obligations of the parties shall be governed and construed in accordance with the laws of the Commonwealth of Massachusetts. Any action brought pursuant to or in connection with this Agreement shall be brought only in the state or federal courts within the Commonwealth of Massachusetts without regard to its conflict of laws provisions. In any such action, Consultant submits to the personal jurisdiction of the courts of the Commonwealth of Massachusetts, waives any objections to venue of such courts, and agrees to accept service of process by any means reasonably calculated to give effective notice of the action. 10.9. Severablility. The provisions of this Agreement are severable and if any of the provisions hereof are held to be invalid, illegal or unenforceable, in whole or in part, the remaining provisions of this Agreement shall remain binding and enforceable by and between the parties. 10.10. Section Headings. Section headings are for convenience only and shall not be considered in the interpretation of this Agreement. 10.11. Independent Contractor. Consultant shall at all times be an independent contractor and not an employee of Axcelis, and nothing herein shall be construed to create a partnership, joint venture, or agency relationship between the parties hereto. Neither party shall have any authority to enter into agreements of any kind on behalf of the other party and shall not have the power or authority to bind or obligate the other party in any manner to any third party. Each party agrees not to represent itself as a partner, joint venturer, agent, employee, or general representative of the other party or to make any representations on the other party's behalf. Consultant shall have sole responsibility for payment, on behalf of itself and any subconsultants or employees, of all federal, state, and local taxes or contributions imposed or required under unemployment insurance, social security and income tax laws and for the filing of all required tax forms with respect to any amounts paid by Axcelis to Consultant hereunder. Consultant shall not be entitled to any benefits, coverages, or other privileges, including, without limitation, unemployment, medical, pension, or other employee welfare benefits and payments provided to employees of Axcelis. IN WITNESS WHEREOF, the parties hereto have executed and delivered this Agreement as of the date first above written. AXCELIS TECHNOLOGIES, INC. By: /s/ Mary G. Puma_______________ Mary G. Puma, Chief Executive Officer CONSULTANT /s/ Stephen G. Bassett______________ Stephen G. Bassett Schedule 1 Services To provide consulting services as an interim Chief Financial Officer reporting to the Chief Executive Officer. As such Consultant is responsible for managing all financial operations and strategy, investor relations and business development of the company. As the corporation's top financial officer, this position is responsible for assisting the Audit Committee of the Board of Directors in managing the company's external auditors and internal audit processes. In addition, the Consultant will oversee: * SEC reporting * Tax planning * Treasury function * Relationships with analysts and investors * Credit relationships * Business development transactions. Time Commitments The Consultant will provide full time services (approximately 40 hours a week). Reimbursable Expenses Axcelis shall pay or promptly, no later than 30 days upon the receiving of the related expense statement submitted by Consultant, reimburse Consultant for all reasonable travel, long-distance telephone, entertainment and other business expenses paid or incurred by Consultant in connection with the performance of Consultant's duties hereunder (as long as the requirements of Section 3.2 of the Agreement are met), upon presentation of expense statements, vouchers or other evidence of expenses providing the reasonable detail required by the Corporation. Schedule 2 Compensation and Billing Procedures In consideration of the Services described in Schedule 1, Consultant shall be paid at the weekly rate of US$5,750, payable every two (2) weeks in arrears. The bi-weekly payment shall be US$11,500, and shall be paid by check or wire transfer to a bank account designated by Consultant. Upon Axcelis' engagement of a permanent Chief Financial Officer (other than the Consultant) during the term of this Agreement (including any renewal term) or within 30 days thereafter, Axcelis shall make a lump sum payment to Consultant in the amount of US$23,000 (the "Success Fee"), which shall be paid by check or wire transfer to a bank account designated by Consultant. EX-31 4 ex31_1.htm CERTIFICATION OF CEO

CERTIFICATION
of the Principle Executive Officer of Axelis Technologies, Inc.
under Section 302 of the Sarbanes-Oxley Act of 2002

I, Mary G. Puma, certify that:

1.   I have reviewed this Form 10-Q of Axcelis Technologies, Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.   The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)   Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c)   Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.   The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 13, 2003

By:  /s/ Mary G. Puma

Mary G. Puma

President and Chief Executive Officer

EX-31 5 ex31_2.htm CERTIFICATION OF CFO

CERTIFICATION
of the Principle Financial Officer of Axelis Technologies, Inc.
under Section 302 of the Sarbanes-Oxley Act of 2002

I, Stephen G. Bassett, certify that:

1.   I have reviewed this Form 10-Q of Axcelis Technologies, Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.   The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)   Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c)   Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.   The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 13, 2003

By:  /s/ Stephen G. Bassett

Stephen G. Bassett

Chief Financial Officer

EX-32 6 ex32_1.htm CERTIFICATION OF CEO

EXHIBIT 32.1

AXCELIS TECHNOLOGIES, INC.

Certification of the Chief Executive Officer

Pursuant to Section 1350 of Chapter 63 of title 18 of the United States Code

The undersigned Chief Executive Officer of Axcelis Technologies, Inc., a Delaware corporation, hereby certify, for the purposes of Section 1350 of Chapter 63 of title 18 of the United States Code (as implemented by Section 906 of the Sarbanes-Oxley Act of 2002) as follows:

     This Form 10-Q quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and the information contained herein fairly presents, in all material respects, the financial condition and results of operations of the Company.

     IN WITNESS WHEREOF, the undersigned have executed this Certification as of August 13, 2003.

/s/ Mary G. Puma

Mary G. Puma

Chief Executive Officer of Axcelis Technologies, Inc.

EX-32 7 ex32_2.htm CERTIFICATION OF CFO

EXHIBIT 32.2

AXCELIS TECHNOLOGIES, INC.

Certification of the Chief Financial Officer

Pursuant to Section 1350 of Chapter 63 of title 18 of the United States Code

The undersigned Chief Financial Officer of Axcelis Technologies, Inc., a Delaware corporation, hereby certify, for the purposes of Section 1350 of Chapter 63 of title 18 of the United States Code (as implemented by Section 906 of the Sarbanes-Oxley Act of 2002) as follows:

     This Form 10-Q quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and the information contained herein fairly presents, in all material respects, the financial condition and results of operations of the Company.

     IN WITNESS WHEREOF, the undersigned have executed this Certification as of August 13, 2003.

/s/ Stephen G. Bassett

Stephen G. Bassett

Chief Financial Officer of Axcelis Technologies, Inc.

EX-99 8 ex99_1.txt FACTORS AFFECTING FUTURE OPERATING RESULTS Exhibit 99.1 AXCELIS TECHNOLOGIES, INC. Form 10-Q for the quarter ended June 30, 2003 FACTORS AFFECTING FUTURE OPERATING RESULTS From time to time, we may make forward-looking public statements, such as statements concerning our then expected future revenues or earnings or concerning the prospects for our markets or our product development, projected plans, performance, order procurement as well as other estimates relating to future operations. Forward-looking statements may be in reports filed under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), in registration statements filed under the Securities Act of 1933, as amended (the "Securities Act"), in press releases or informal statements made with the approval of an authorized executive officer. The words or phrases "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the meaning of Section 21E of the Exchange Act and Section 27A of the Securities Act, as enacted by the Private Securities Litigation Reform Act of 1995. We wish to caution you not to place undue reliance on these forward-looking statements which speak only as of the date on which they are made. In addition, we wish to advise you that the factors listed below, as well as other factors that we may or may not have not currently identified, could affect our financial or other performance and could cause our actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods or events in any current statement. We will not undertake and specifically decline any obligation to publicly release revisions to these forward-looking statements to reflect either circumstances after the date of the statements or the occurrence of events which may cause us to re-evaluate our forward-looking statements. In connection with the "safe harbor" provisions of the Private Securities Litigation Reform Act, we are hereby filing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements made by us or on our behalf. If semiconductor manufacturers do not make sufficient capital expenditures, our sales and profitability will be harmed. We anticipate that a significant portion of our new orders will depend upon demand from semiconductor manufacturers who build or expand fabrication facilities. If the rate of construction or expansion of fabrication facilities declines, demand for our systems will decline, reducing our revenues. This would also hurt our profitability, because our continued investments in engineering, research and development and marketing necessary to develop new products and to maintain extensive customer service and support capabilities limit our ability to reduce expenses in proportion to declining sales. A number of factors may cause semiconductor manufacturers to make reduced capital expenditures, including the following. Downturns in the semiconductor industry may further reduce demand for our products, harming our sales and profitability. The semiconductor business is highly cyclical and the industry has been in a severe down cycle since early in 2001, the length of which cannot be predicted. This continues to reduce demand for new or expanded fabrication facilities. Any continuing weakness or future downturns or slowdowns in the industry may adversely affect our financial condition. Oversupply in the semiconductor industry reduces demand for capital equipment, including our products. Inventory buildups in the semiconductor industry, resulting in part from the down cycle, have produced a current oversupply of semiconductors. This has caused semiconductor manufacturers to revise capital spending plans, resulting in reduced demand for capital equipment such as our products. If this oversupply is not reduced by increasing demand from the various electronics industries that use semiconductors, which we cannot accurately predict, our sales and profitability will be harmed. Industry consolidation and outsourcing of semiconductor manufacturing may reduce the number of our potential customers, harming our revenues. The substantial expense of building, upgrading or expanding a semiconductor fabrication facility is increasingly causing semiconductor companies to contract with foundries to manufacture their semiconductors. In addition, consolidation and joint venturing within the semiconductor manufacturing industry is increasing. We expect these trends to continue, which will reduce the number of our potential customers. This increased concentration of our customers potentially makes our revenues more volatile as a higher percentages of our total revenues are tied to a particular customer's buying decisions. If we fail to develop and introduce reliable new or enhanced products and services that meet the needs of semiconductor manufacturers, our results will suffer. Rapid technological changes in semiconductor manufacturing processes require us to respond quickly to changing customer requirements. Our future success will depend in part upon our ability to develop, manufacture and successfully introduce new systems and product lines with improved capabilities and to continue to enhance existing products, including products that process 300 millimeter wafers. This will depend upon a variety of factors, including new product selection, timely and efficient completion of product design and development and of manufacturing and assembly processes, product performance in the field and effective sales and marketing. In particular: * We must develop the technical specifications of competitive new systems, or enhancements to our existing systems, and manufacture and ship these systems or enhancements in volume in a timely manner. * We will need to accurately predict the schedule on which our customers will be ready to transition to new products, in order to accurately forecast demand for new products while managing the transition from older products. * We will need to effectively manage product reliability or quality problems that often exist with new systems, in order to avoid reduced orders, higher manufacturing costs, delays in acceptance and payment and additional service and warranty expenses. * Our new products must be accepted in the marketplace. Our failure to meet any of these requirements will have a material adverse effect on our operating results and profitability. If we fail to compete successfully in the highly competitive semiconductor equipment industry, our sales and profitability will decline. The market for semiconductor manufacturing equipment is highly competitive and includes companies with substantially greater financial, engineering, manufacturing, marketing and customer service and support resources than we have that may be better positioned to compete successfully in the industry. In addition, there are smaller, emerging semiconductor equipment companies that provide innovative systems with technology that may have performance advantages over our systems. Competitors are expected to continue to improve the design and performance of their existing products and processes and to introduce new products and processes with improved price and performance characteristics. If we are unable to improve or introduce competing products when demanded by the markets, our business will be harmed. In addition, if competitors enter into strategic relationships with leading semiconductor manufacturers covering products similar to those sold or being developed by us, our ability to sell products to those manufacturers may be adversely affected. We have been dependent on sales to a limited number of large customers; the loss of any of these customers or any reduction in orders from them could materially affect our sales. Historically, we have sold a significant proportion of our products and services to a limited number of fabricators of semiconductor products. For example, in 2002, one of our customers, IBM, accounted for 14% of our net sales, and our top ten customers accounted for 64% of our net sales. None of our customers has entered into a long-term agreement requiring it to purchase our products. Although the composition of the group comprising our largest customers has varied from year to year, the loss of a significant customer or any reduction or delays in orders from any significant customer, including reductions or delays due to customer departures from recent buying patterns, or market, economic or competitive conditions in the semiconductor industry, could adversely affect us. The ongoing consolidation of semiconductor manufacturers may also increase the harmful effect of losing a significant customer. Our quarterly financial results may fluctuate significantly and may fall short of anticipated levels. We derive most of our revenues from the sale of a relatively small number of expensive products to a small number of customers. The list prices on these products range from $200,000 to over $4.0 million. At our current sales level, each sale, or failure to make a sale, could have a material effect on us in a particular quarter. Our lengthy sales cycle, coupled with customers' competing capital budget considerations, make the timing of customer orders uneven and difficult to predict. In a given quarter, a number of factors can adversely affect our revenues and results, including changes in our product mix, increased fixed expenses per unit due to reductions in the number of products manufactured, and higher fixed costs due to increased levels of research and development and expansion of our worldwide sales and marketing organization. Our gross margins also may be affected by the introduction of new products. We typically become more efficient in producing our products as they mature. For example, our gross margins in 2001 and 2002 were adversely affected in part as a result of the increased proportion of systems sold to process 300 millimeter wafers. In addition, our backlog at the beginning of a quarter typically does not include all orders required to achieve our sales objectives for that quarter and is not a reliable indicator of our future sales. As a result, our net sales and operating results for a quarter depend on our shipping orders as scheduled during that quarter as well as obtaining new orders for products to be shipped in that same quarter. Any delay in, or cancellation of, scheduled shipments or in shipments from new orders could materially and adversely affect our financial results. Due to the foregoing factors, we believe that period-to-period comparisons of our operating results should not be relied upon as an indicator of our future performance. We access the important Japanese market for ion implant through a joint venture which we do not control. We own 50% of the equity of a Japanese corporation called Sumitomo Eaton Nova or SEN, to which we have granted an exclusive license to manufacture and sell ion implanters in Japan. The remaining 50% of the equity is owned by Sumitomo Heavy Industries, Ltd., a Japanese manufacturer of industrial machinery and shipbuilding. Our joint venture agreement with Sumitomo gives both owners veto rights, so that neither of us alone can effectively control SEN. SEN's business is subject to the same risks as our business. Royalties and income from SEN have been a substantial contribution to our earnings, and a substantial decline in SEN's sales and income from operations could have a material adverse effect on our net income. As a result of this joint venture structure, we have less control over SEN management than over our own management and may not have timely knowledge of factors affecting SEN's business. In addition, given the equal balance of ownership, it is possible that the SEN Board may be unable to reach consensus from time to time. Neither Axcelis or Sumitomo has the right to buy out the other's interest in SEN and the SEN joint venture is perpetual, although termination provisions in the license agreement allow either SEN or Axcelis to effectively terminate the joint venture at the end of 2004. SEN has been a very valuable partner to Axcelis since its formation and we expect to renew our license to SEN for a further 5 year term. From time to time, we have allowed SEN to sell implanters outside of Japan. We allow these sales when the customer requests SEN products. Such requests tend to occur when SEN customers participate, as joint venturers or technical advisors, in fabrication facilities outside of Japan. In those cases, the financial benefit to Axcelis from the sale of a SEN implanter is less than the financial benefit of a sale of an Axcelis implanter, but our primary goal to satisfy our customer with the product of their choice. When these sales are allowed, we act as exclusive agent for SEN to manage the terms of the sales and to ensure that they are consistent with our global product and customer strategies. We receive commissions from SEN on these extra-territorial sales and assume most of the post-installation warranty responsibility. A decline in sales of our products and services to customers outside the United States would hurt our business and profits. We are substantially dependent on sales of our products and services to customers outside the United States, which accounted for approximately 70% 62% and 51%, of our net sales in 2000 and 2001 and 2002, respectively. We anticipate that international sales will continue to account for a significant portion of our net sales. Because of our dependence upon international sales, our results and prospects may be adversely affected by a number of factors, including: * unexpected changes in laws or regulations resulting in more burdensome governmental controls, tariffs, restrictions, embargoes or export license requirements; * difficulties in obtaining required export licenses; * volatility in currency exchange rates; * political and economic instability, particularly in Asia; * difficulties in accounts receivable collections; * extended payment terms beyond those customarily offered in the United States; * difficulties in managing distributors or representatives outside the United States; * difficulties in staffing and managing foreign subsidiary and branch operations; and * potentially adverse tax consequences. Making more sales denominated in foreign currencies to counteract the strong dollar may expose us to additional risks that could hurt our results. Substantially all of our sales to date have been denominated in U.S. dollars. Our products become less price competitive in countries with currencies that are declining in value in comparison to the dollar. This could cause us to lose sales or force us to lower our prices, which would reduce our gross margins. Our equity income and royalty income from SEN are denominated in Japanese yen, which exposes us to some risk of currency fluctuations. If it becomes necessary for us to make more sales denominated in foreign currencies to counteract the strong dollar, we will become more exposed to these risks. We may not be able to maintain and expand our business if we are not able to retain, hire and integrate additional qualified personnel. Our business depends on our ability to attract and retain qualified, experienced employees. There is substantial competition for experienced engineering, technical, financial, sales and marketing personnel in our industry. In particular, we must attract and retain highly skilled design and process engineers. Competition for such personnel is intense, particularly in the areas where we are based, including the Boston metropolitan area and the Rockville, Maryland area, as well as in other locations around the world. If we are unable to retain our existing key personnel, or attract and retain additional qualified personnel, we may from time to time experience levels of staffing inadequate to develop, manufacture and market our products and perform services for our customers. As a result, our growth could be limited or we could fail to meet our delivery commitments or experience deterioration in service levels or decreased customer satisfaction, all of which could adversely affect our financial results and cause the value of our notes and stock to decline. Our dependence upon a limited number of suppliers for many components and sub-assemblies could result in increased costs or delays in manufacture and sales of our products. We rely to a substantial extent on outside vendors to manufacture many of the components and subassemblies of our products. We obtain many of these components and sub-assemblies from either a sole source or a limited group of suppliers. Because of our reliance on outside vendors generally, and on a limited group of suppliers in particular, we may be unable to obtain an adequate supply of required components on a timely basis, on price and other terms acceptable to us, or at all. In addition, we often quote prices to our customers and accept customer orders for our products before purchasing components and subassemblies from our suppliers. If our suppliers increase the cost of components or subassemblies, we may not have alternative sources of supply and may not be able to raise the price of our products to cover all or part of the increased cost of components. The manufacture of some of these components and subassemblies is an extremely complex process and requires long lead times. As a result, we have in the past and may in the future experience delays or shortages. If we are unable to obtain adequate and timely deliveries of our required components or subassemblies, we may have to seek alternative sources of supply or manufacture these components internally. This could delay our ability to manufacture or to ship our systems on a timely basis, causing us to lose sales, incur additional costs, delay new product introductions and suffer harm to our reputation. In certain circumstances, we may need additional capital. Our capital requirements may vary widely from quarter to quarter, depending on, among other things, capital expenditures, fluctuations in our operating results, financing activities, acquisitions and investments and inventory and receivables management. We believe that our available cash, our credit line and our future cash flow from operations will be sufficient to satisfy our working capital, capital expenditure and research and development requirements for the foreseeable future. This, of course, depends on the accuracy of our assumptions about levels of sales and expenses, and a number of factors, including those described in these "Risk Factors," could cause us to require additional capital from external sources. In addition, in the future, we may require or choose to obtain additional debt or equity financing in order to finance acquisitions or other investments in our business. Depending on market conditions, future equity financings may not be possible on attractive terms and would be dilutive to the existing holders of our common stock and convertible notes. Our existing credit agreement contains restrictive covenants and future debt financings could involve additional restrictive covenants, all of which may limit the manner in which we conduct our business. We may incur costly litigation to protect our proprietary technology, and if unsuccessful, we may lose a valuable asset or experience reduced market share. We rely on a combination of patents, copyrights, trademark and trade secret laws, non-disclosure agreements and other intellectual property protection methods to protect our proprietary technology. Despite our efforts to protect our intellectual property, our competitors may be able to legitimately ascertain the non-patented proprietary technology embedded in our systems. If this occurs, we may not be able to prevent their use of this technology. Our means of protecting our proprietary rights may not be adequate and our patents may not be sufficiently broad to prevent others from using technology that is similar to or the same as our technology. In addition, patents issued to us have been, or might be challenged, and might be invalidated or circumvented and any rights granted under our patents may not provide adequate protection to us. Our competitors may independently develop similar technology, duplicate features of our products or design around patents that may be issued to us. As a result of these threats to our proprietary technology, we may have to resort to costly litigation to enforce or defend our intellectual property rights. On January 8, 2001, we filed a lawsuit against Applied Materials, Inc. ("Applied") in the United States District Court for the District of Massachusetts. The complaint alleges that Applied's medium current/high energy ion implanter machine launched in November 2000 infringes our patent for ion implantation equipment using radio frequency linear accelerator technology. We have also alleged that Applied unlawfully interfered with our existing and future contracts. On January 18, 2001, we filed a motion for a preliminary injunction for the reason, among others, that infringement at the time of industry transition between equipment capable of handling 200 millimeter wafers and equipment capable of handling 300 millimeter wafers would irreparably harm us. Through this motion, we asked the court to stop Applied from manufacturing, selling or offering to sell its medium current/high energy ion implanter machine and to order Applied to remove all our patented technology from implanters that Applied may have placed in chipmakers' plants for process development trials. Applied filed counterclaims of unfair competition, defamation and tortious interference with prospective economic advantage, all of which, it contends, arise from certain communications we allegedly made about the lawsuit and its claims of infringement. In December 2002 the court issued a claim construction, interpreting the scope of our patent. In March 2003 the court made summary judgement rulings in light of the claim construction, narrowing the scope of the infringement issues to be determined by a jury in a trial set for June 2003. We believe our claims are meritorious and intend to pursue the matter vigorously. Although there can be no assurance of a favorable outcome and we have incurred significant legal expenses to pursue this litigation, we do not believe that our pursuit of this matter will have a material adverse effect on our financial condition, results of operations or liquidity. In the event that Applied is found not to have infringed, we expect that Applied will continue to sell its medium current/high energy implanter as a new and substantial competitor for sales of high energy/medium current ion implantation equipment. We might face intellectual property infringement claims or patent disputes that may be costly to resolve and, if resolved against us, could be very costly to us and prevent us from making and selling our systems. From time to time, claims and proceedings have been or may be asserted against us relative to patent validity or infringement matters. Our involvement in any patent dispute or other intellectual property dispute or action to protect trade secrets, even if the claims are without merit, could be very expensive to defend and could divert the attention of our management. Adverse determinations in any litigation could subject us to significant liabilities to third parties, require us to seek costly licenses from third parties and prevent us from manufacturing and selling our systems. Any of these situations could have a material adverse effect on us and cause the value of our common stock to decline. -----END PRIVACY-ENHANCED MESSAGE-----

EX-10

Exhibit 10.10
AXCELIS TECHNOLOGIES, INC.
INDEPENDENT CONSULTANT AGREEMENT


This Agreement is entered into effective this 9th day of
June, 2003  by and between Axcelis Technologies, Inc., a
Delaware corporation with its principal office at 55
Cherry Hill Drive, Beverly, Massachusetts  01915 ("Axcelis")
and Stephen G. Bassett, with an address at 2 Keystone Way,
Andover, Massachusetts ("Consultant").

In consideration of the mutual covenants and promises
contained herein, Axcelis and Consultant agree as follows:

1. Performance of Services.  Consultant agrees to provide to
Axcelis the services generally described in Schedule 1 (the
"Services").  Consultant shall supply all necessary supplies
and materials and shall be solely responsible for requesting
any information necessary from Axcelis for the performance of
the Services.  Consultant shall not employ any subcontractors
for any of the Services without the prior written approval of
Axcelis, and Consultant shall remain responsible for the
performance of any such subcontractors.  Consultant shall
perform the Services in accordance with the  professional
standards of skill, care, and diligence.

2. Time.  Consultant agrees to adhere to the time commitments
set forth in Schedule 1 or as otherwise mutually agreed upon.
Consultant shall perform the Services as expeditiously as is
consistent with the standards of professional skill and care
required hereby.  Consultant shall perform the Services in
coordination with the operations of Axcelis and with any party
engaged by Axcelis in connection with the Services being
performed.

3. Payment.

3.1.   	Fees.	For the Services provided by Consultant under
this Agreement, Axcelis agrees to compensate Consultant
according to Schedule 2.

3.2.   	Reimbursable Expenses.  Axcelis shall compensate
Consultant for reasonable expenses actually incurred by
Consultant to the extent provided in Schedule 1 ("Reimbursable
Expenses"). Consultant agrees that if such expenses are for
travel, Consultant shall either (i) use Axcelis' travel partner
or (ii) limit its travel expenses such that Consultant's expenses
do not exceed those quoted by Axcelis' travel partner (as per the
Axcelis Travel Policy for Independent Contractors and Temporary
Workers). Consultant agrees to use reasonable efforts to minimize
Reimbursable Expenses.

4. [Intentionally Omitted]

5. Inventions.

5.1.  	Definition and Disclosure.  As used in this Agreement,
"Inventions" shall mean any and all ideas, concepts, discoveries,
inventions, developments, trade secrets, methods, data, information,
improvements, materials, Work Product (as defined in Section 5.4
below), and know-how that are conceived, devised, invented,
developed or reduced to practice or tangible medium (whether or
not protectible under state, federal or foreign patent, copyright,
trade secrecy or similar laws), by Consultant, under Consultant's
direction or jointly with others during any period that Consultant
is engaged by Axcelis, which relate, directly or indirectly, to the
business of Axcelis and arise out of Consultant's performance of this
Agreement.  Consultant agrees promptly to disclose all Inventions
to Axcelis.

5.2.  	Assignment of Rights.  Consultant covenants and agrees that
all right, title and interest in any Inventions shall remain the
sole and exclusive property of Corporation and shall be a work made
for hire. Consultant hereby assigns and agrees to assign to Axcelis
all of Consultant's right, title and interest in and to the Inventions
and any and all related patent rights, copyrights, and other
intellectual property rights and applications and registrations
therefor.  During and after Consultant's engagement by Axcelis,
Consultant shall cooperate with Axcelis, at Axcelis' expense, in
obtaining protection for the Inventions and Consultant shall execute
all documents which Axcelis shall reasonably request in order to
perfect Axcelis' rights in the Inventions.  Consultant hereby appoints
Axcelis as Consultant's attorney to execute and deliver any such
documents on Consultant's behalf in the event Consultant should fail
or refuse to do so within a reasonable period following Axcelis'
request.

5.3.  	No Conflict.	Consultant represents and warrants that
the assignment of Inventions to Axcelis or Axcelis' use of such
Inventions shall not violate the copyright, patent, trademark,
trade secret, or other right of any person or entity and no
additional permissions, clearances, assignments, or licenses are
necessary in order for Axcelis to own, use, and commercialize the
Work Product (as defined below) and other Inventions.

5.4.  	Work Product.  Without limiting the generality of the
foregoing, Consultant further agrees that all right, title, and
interest in and to any works of authorship or copyrightable materials
resulting from the performance of the Services under this Agreement
and all copies thereof, in whatever media (the "Work Product") shall
be in Axcelis and shall be "works made for hire" within the meaning
of the Copyright Law of the United States and may be used by Axcelis
(or such parties as Axcelis may designate) thereafter in such manner
and for such purposes as Axcelis (or such parties as Axcelis may
designate) may deem advisable, without further employment of or
additional compensation to Consultant.  To the extent that the Work
Product does not qualify for work made for hire status, Consultant
hereby assigns and agrees to assign the entire worldwide, perpetual
copyright in and to the Work Product to Axcelis pursuant to Section
5.2.


6. Confidentiality.

6.1.  	Definition.  Consultant understands that Axcelis
continually obtains and develops valuable proprietary and
confidential information concerning its scientific, technical,
or business affairs (the "Confidential Information") which may
become known to Consultant in connection with Consultant's
engagement by Axcelis. By way of illustration, but not limitation,
Confidential Information includes Inventions and may include trade
secrets, technical information, know-how, research and development
activities of Axcelis, product and marketing plans, customer and
supplier information and information disclosed to Axcelis or to
Consultant by third parties of a proprietary or confidential nature
or under an obligation of confidence.  Confidential Information may
be contained in various media, including without limitation, patent
applications, research data and observations, computer programs in
object and/or source code, technical specifications, laboratory
notebooks, supplier and customer lists, internal financial data and
other documents and records of Axcelis.

6.2.  	Proprietary Rights.  Consultant acknowledges that all
Confidential Information, either in writing and labeled or
identified as confidential or proprietary or identified orally
prior to disclosure by Axcelis as confidential or proprietary,
is and shall remain the exclusive property of Axcelis or the third
party providing such information to Consultant or Axcelis.
Consultant agrees that Consultant shall not, during the term of
Consultant's engagement by Axcelis and thereafter, publish,
disclose or otherwise make available to any third party, other
than employees of Axcelis, any Confidential Information except
as expressly authorized in writing by Axcelis.  Consultant agrees
that Consultant shall use such Confidential Information only in
the performance of Consultant's duties for Axcelis and in accordance
with any Axcelis policies with respect to the protection of
Confidential Information.  Consultant agrees not to use such
Confidential Information for Consultant's own benefit or for the
benefit of any other person or business entity.

6.3.  	Precautions.  Consultant agrees to exercise all reasonable
precautions to protect the integrity and confidentiality of
Confidential Information in Consultant's possession and not to
remove any materials containing Confidential Information from
Axcelis' premises except to the extent necessary to Consultant's
performance of the Services.  Upon the termination of Consultant's
engagement hereunder, or at any time upon Axcelis' request,
Consultant shall return immediately to Axcelis any and all materials
containing any Confidential Information then in Consultant's
possession or under Consultant's control.

6.4.  	Exceptions.  Confidential Information shall not include
information which (a) is or becomes generally known within Axcelis'
industry through no fault of Consultant; (b) was known to Consultant
at the time it was disclosed as evidenced by Consultant's written
records at the time of disclosure; (c) is lawfully and in good faith
made available to Consultant by a third party who did not derive it
from Axcelis and who imposes no obligation of confidence on
Consultant; or (d) is required to be disclosed by law or by a
governmental authority or by order of a court of competent
jurisdiction, provided that such disclosure is subject to all
applicable governmental or judicial protection available for
like material and reasonable advance notice is given to Axcelis.


7. Exclusivity; Non-Solicitation.

7.1.   	Exclusivity and Non-Compete.  Consultant shall not, during
the term of this Agreement, and for a period of one (1) year
thereafter, organize or serve in any capacity (whether as an officer,
director, employee, consultant or otherwise) any person, firm,
corporation or other entity which is in direct competition with
Axcelis or which may otherwise give rise to a conflict of interest
or appearance of a conflict of interest with Consultant's
performance of the Services, without the prior written consent
of Axcelis.

7.2.   	Non-Solicitation.  Consultant agrees that during the term
of this Agreement and for a period of one (1) year thereafter,
Consultant shall not induce or attempt to induce any of Axcelis'
employees or independent contractors to terminate their employment
or contractual relationships with Axcelis, or solicit, divert or
take away, or attempt to divert or take away the business or
patronage of any of the clients, customers or accounts, or
prospective clients, customers or accounts of Axcelis which
were contracted, solicited or served by Axcelis during the
period in which Consultant was performing the Services for Axcelis.


8.  	Third Party Agreements and Rights.

8.1.  	No Conflict with Other Contracts.  Consultant represents
that Consultant's performance under this Agreement does not and
shall not breach any fiduciary or other duty or any covenant,
agreement or understanding (including, without limitation, any
agreement relating to assignment of inventions, proprietary
information, knowledge or data) to which Consultant is a party
or by the terms of which Consultant may be bound.

8.2.  	Third Party Proprietary Rights.  Consultant understands
and acknowledges that Axcelis does not desire to acquire from
Consultant any trade secrets, know-how, or confidential
information Consultant may have acquired from third parties.
Consultant therefore agrees that Consultant will not improperly
use or disclose any proprietary information or trade secrets of
any person or entity with whom Consultant owes a duty to keep
such information in confidence.

9.  	Termination of Agreement.

9.1.  	Term.  This Agreement shall expire on September 5, 2003,
unless expressly renewed by the parties.  After such date,
Consultant agrees to make his Services available to Axcelis on a
month -to-month basis at Axcelis' option, unless Consultant gives
Axcelis 30 days prior notice of Consultant's unavailability to
continue to provide such Services.  The date of September 5, 2003
or any later expiration date agreed to by the parties is referred
to herein as the "Expiration Date."

9.2.  	By Axcelis.  Axcelis may terminate this Agreement prior
to the Expiration Date as follows:

(a) without cause, on 30 days' prior written notice; or
(b) immediately, by written notice to Consultant, if Consultant
fails to perform or observe any of the terms, covenants,
obligations or conditions of this Agreement.
9.3.  	By Consultant.  Consultant may terminate this Agreement
prior to its Expiration Date as follows:

(a) without cause, on 30 days' prior written notice, or

(b)  upon 10 days written notice to Axcelis, if Axcelis fails to
make payments required under Section 3 above and Schedule 2.

9.4.   	Effect of Termination.  In the event of termination by
Axcelis prior to the Expiration Date, without cause, Axcelis
shall promptly make the payments set forth on Schedule 2  as if
the Consultant provided Services through the Expiration Date.
The Success Fee, as described on Schedule 2, shall be paid when
due.  In the event of termination, Consultant shall promptly
deliver to Axcelis all equipment and supplies belonging to Axcelis
and all documents, work papers, studies, calculations, computer
programs, data, drawings, plans, specifications and other tangible
work product or materials pertaining to the Inventions and/or the
Services performed under this Agreement to the time of termination.
Any termination of this Agreement shall not affect or impair the
right of Axcelis to recover damages occasioned by any default of
Consultant or to set off such damages against amounts otherwise
owed to Consultant. Any termination of this Agreement shall not
affect or impair the right of Consultant to recover any payment
due under this Agreement.  Sections 5, 6, and 7, this Section 9.4
and Section 10 shall continue in full force and effect not
withstanding the expiration or termination of this Agreement
for any reason.

10.  Miscellaneous.

10.1. Full Power and Authority.  Each party represents and
warrants that it has full power and authority to undertake
the obligations set forth in this Agreement and that it has
not entered into any other agreements that would render it
incapable of satisfactorily performing its obligations hereunder.

10.2.  Compliance with Law.  Consultant shall perform the
Services hereunder in compliance with all applicable federal,
state and municipal laws, regulations, codes, ordinances and
orders, and any permit conditions in effect as of the time of
such performance.

10.3. Consultant's Accounting Records. 	Consultant shall keep
records pertaining to the Services performed and Reimbursable
Expenses employing sound bookkeeping practices and in accordance
with generally accepted accounting principles.  All records
pertaining to the Services performed and Reimbursable Expenses
shall be available to Axcelis or its authorized representatives
for review and audit during normal business hours upon reasonably
prior written notice to Consultant.

10.4. Non-Assignable.  The Services are personal to Consultant
and Consultant shall not assign, sublicense, or transfer any of
its obligations, responsibilities, rights or interests (including,
without limitation, its right to receive any moneys due hereunder)
under this Agreement without the written consent of Axcelis.
The Services may not be assumed by or assigned by a trustee in
bankruptcy.  Any assignment, subletting, or transfer by Consultant
in violation of this Section 10.4 shall be void and without force
or effect.

10.5. Entire Agreement.  This Agreement represents the entire and
integrated agreement between Axcelis and Consultant with respect
to the subject matter hereof and supersedes all prior negotiations,
representations or agreements, either written or oral. This
Agreement may be amended only by written instrument signed by
both Axcelis and Consultant.

10.6. Limitation of Liability.  No officer, director, member,
employee, or other principal, agent or representative (whether
disclosed or undisclosed) of Axcelis shall be personally liable
to Consultant hereunder, for Axcelis' payment obligations or
otherwise.  Consultant hereby agrees to look solely to the assets
of Axcelis for the satisfaction of any liability of Axcelis hereunder.
In no event shall Axcelis be liable to Consultant for indirect,
incidental, special, reliance, exemplary, or consequential damages.

10.7. No Inadvertent Waivers.  No waiver of any portion of this
Agreement shall be effective unless in writing.  The failure of
Axcelis at any time to require performance by Consultant of any
provision shall in no way affect the right of Axcelis to enforce
that or any other provision of this Agreement.  No waiver of any
breach of this Agreement shall constitute a waiver of any subsequent
breach of the same or any other provision of this Agreement.

10.8. Governing Law.  This Agreement and the rights and obligations
of the parties shall be governed and construed in accordance with the
laws of the Commonwealth of Massachusetts.  Any action brought pursuant
to or in connection with this Agreement shall be brought only in the
state or federal courts within the Commonwealth of Massachusetts
without regard to its conflict of laws provisions.  In any such action,
Consultant submits to the personal jurisdiction of the courts of the
Commonwealth of Massachusetts, waives any objections to venue of such
courts, and agrees to accept service of process by any means
reasonably calculated to give effective notice of the action.

10.9. Severablility.  The provisions of this Agreement are severable
and if any of the provisions hereof are held to be invalid, illegal
or unenforceable, in whole or in part, the remaining provisions of
this Agreement shall remain binding and enforceable by and between
the parties.
10.10. Section Headings.  Section headings are for convenience only
and shall not be considered in the interpretation of this Agreement.

10.11. Independent Contractor.  Consultant shall at all times be an
independent contractor and not an employee of Axcelis, and nothing
herein shall be construed to create a partnership, joint venture, or
agency relationship between the parties hereto.  Neither party shall
have any authority to enter into agreements of any kind on behalf of
the other party and shall not have the power or authority to bind or
obligate the other party in any manner to any third party.  Each party
agrees not to represent itself as a partner, joint venturer, agent,
employee, or general representative of the other party or to make any
representations on the other party's behalf.  Consultant shall have
sole responsibility for payment, on behalf of itself and any
subconsultants or employees, of all federal, state, and local taxes
or contributions imposed or required under unemployment insurance,
social security and income tax laws and for the filing of all required
tax forms with respect to any amounts paid by Axcelis to Consultant
hereunder.  Consultant shall not be entitled to any benefits, coverages,
or other privileges, including, without limitation, unemployment, medical,
pension, or other employee welfare benefits and payments provided to
employees of Axcelis.

		IN WITNESS WHEREOF, the parties hereto have executed
and delivered this Agreement as of the date first above written.
AXCELIS TECHNOLOGIES, INC.

By: /s/ Mary G. Puma_______________
Mary G. Puma, Chief Executive Officer


CONSULTANT

/s/ Stephen G. Bassett______________
Stephen G. Bassett


Schedule 1

Services
To provide consulting services as an interim Chief Financial
Officer reporting to the Chief Executive Officer.  As such
Consultant is responsible for managing all financial operations
and strategy, investor relations and business development  of
the company.  As the corporation's top financial officer, this
position is responsible for assisting the Audit Committee of
the Board of Directors in managing the company's external
auditors and internal audit processes.    In addition, the
Consultant will oversee:

* SEC reporting
* Tax planning
* Treasury function
* Relationships with analysts and investors
* Credit relationships
* Business development transactions.


Time Commitments
The Consultant will provide full time services
(approximately 40 hours a week).

Reimbursable Expenses

Axcelis shall pay or promptly, no later than 30 days
upon the receiving of the related expense statement
submitted by Consultant,  reimburse Consultant for all
reasonable travel, long-distance telephone, entertainment
and other business expenses paid or incurred by Consultant
in connection with the performance of Consultant's duties
hereunder (as long as the requirements of Section 3.2 of
the Agreement are met), upon presentation of expense
statements, vouchers or other evidence of expenses providing
the reasonable detail required by the Corporation.


Schedule 2

Compensation and Billing Procedures

In consideration of the Services described in Schedule 1,
Consultant shall be paid at the weekly rate of US$5,750,
payable every two (2) weeks in arrears.  The bi-weekly
payment shall be US$11,500, and shall be paid by check or
wire transfer to a bank account designated by Consultant.

Upon Axcelis' engagement of a permanent Chief Financial
Officer (other than the Consultant) during the term of
this Agreement (including any renewal term) or within
30 days thereafter, Axcelis shall make a lump sum payment
to Consultant in the amount of US$23,000 (the "Success Fee"),
which shall be paid by check or wire transfer to a bank
account designated by Consultant.

EX-31

CERTIFICATION
of the Principle Executive Officer of Axelis Technologies, Inc.
under Section 302 of the Sarbanes-Oxley Act of 2002

I, Mary G. Puma, certify that:

1.   I have reviewed this Form 10-Q of Axcelis Technologies, Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.   The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)   Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c)   Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.   The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 13, 2003

By:  /s/ Mary G. Puma

Mary G. Puma

President and Chief Executive Officer

EX-31

CERTIFICATION
of the Principle Financial Officer of Axelis Technologies, Inc.
under Section 302 of the Sarbanes-Oxley Act of 2002

I, Stephen G. Bassett, certify that:

1.   I have reviewed this Form 10-Q of Axcelis Technologies, Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.   Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.   The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

a)   Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)   Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

c)   Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.   The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 13, 2003

By:  /s/ Stephen G. Bassett

Stephen G. Bassett

Chief Financial Officer

EX-32

EXHIBIT 32.1

AXCELIS TECHNOLOGIES, INC.

Certification of the Chief Executive Officer

Pursuant to Section 1350 of Chapter 63 of title 18 of the United States Code

The undersigned Chief Executive Officer of Axcelis Technologies, Inc., a Delaware corporation, hereby certify, for the purposes of Section 1350 of Chapter 63 of title 18 of the United States Code (as implemented by Section 906 of the Sarbanes-Oxley Act of 2002) as follows:

     This Form 10-Q quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and the information contained herein fairly presents, in all material respects, the financial condition and results of operations of the Company.

     IN WITNESS WHEREOF, the undersigned have executed this Certification as of August 13, 2003.

/s/ Mary G. Puma

Mary G. Puma

Chief Executive Officer of Axcelis Technologies, Inc.

EX-32

EXHIBIT 32.2

AXCELIS TECHNOLOGIES, INC.

Certification of the Chief Financial Officer

Pursuant to Section 1350 of Chapter 63 of title 18 of the United States Code

The undersigned Chief Financial Officer of Axcelis Technologies, Inc., a Delaware corporation, hereby certify, for the purposes of Section 1350 of Chapter 63 of title 18 of the United States Code (as implemented by Section 906 of the Sarbanes-Oxley Act of 2002) as follows:

     This Form 10-Q quarterly report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and the information contained herein fairly presents, in all material respects, the financial condition and results of operations of the Company.

     IN WITNESS WHEREOF, the undersigned have executed this Certification as of August 13, 2003.

/s/ Stephen G. Bassett

Stephen G. Bassett

Chief Financial Officer of Axcelis Technologies, Inc.

EX-99

Exhibit 99.1
AXCELIS TECHNOLOGIES, INC.

Form 10-Q for the quarter ended June 30, 2003

FACTORS AFFECTING FUTURE OPERATING RESULTS


From time to time, we may make forward-looking public statements,
such as statements concerning our then expected future revenues or
earnings or concerning the prospects for our markets or our product
development, projected plans, performance, order procurement as well
as other estimates relating to future operations. Forward-looking
statements may be in reports filed under the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), in registration statements
filed under the Securities Act of 1933, as amended (the "Securities
Act"), in press releases or informal statements made with the
approval of an authorized executive officer. The words or phrases
"will likely result," "are expected to," "will continue," "is
anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements" within the meaning
of Section 21E of the Exchange Act and Section 27A of the Securities
Act, as enacted by the Private Securities Litigation Reform Act of
1995.

We wish to caution you not to place undue reliance on these
forward-looking statements which speak only as of the date on
which they are made. In addition, we wish to advise you that the
factors listed below, as well as other factors that we may or may
not have not currently identified, could affect our financial or
other performance and could cause our actual results for future
periods to differ materially from any opinions or statements
expressed with respect to future periods or events in any current
statement.

We will not undertake and specifically decline any obligation to
publicly release revisions to these forward-looking statements to
reflect either circumstances after the date of the statements or
the occurrence of events which may cause us to re-evaluate our
forward-looking statements.

In connection with the "safe harbor" provisions of the Private
Securities Litigation Reform Act, we are hereby filing cautionary
statements identifying important factors that could cause our
actual results to differ materially from those projected in
forward-looking statements made by us or on our behalf.

If semiconductor manufacturers do not make sufficient capital
expenditures, our sales and profitability will be harmed.

	We anticipate that a significant portion of our new orders
will depend upon demand from semiconductor manufacturers who build
or expand fabrication facilities. If the rate of construction or
expansion of fabrication facilities declines, demand for our systems
will decline, reducing our revenues. This would also hurt our
profitability, because our continued investments in engineering,
research and development and marketing necessary to develop new
products and to maintain extensive customer service and support
capabilities limit our ability to reduce expenses in proportion
to declining sales.

	A number of factors may cause semiconductor manufacturers to make
reduced capital expenditures, including the following.


Downturns in the semiconductor industry may further reduce demand for our
products, harming our sales and profitability.

	The semiconductor business is highly cyclical and the industry has
been in a severe down cycle since early in 2001, the length of which cannot
be predicted. This continues to reduce demand for new or expanded
fabrication facilities. Any continuing weakness or future downturns or
slowdowns in the industry may adversely affect our financial condition.

Oversupply in the semiconductor industry reduces demand for capital
equipment, including our products.

	Inventory buildups in the semiconductor industry, resulting in part
from the down cycle, have produced a current oversupply of semiconductors.
This has caused semiconductor manufacturers to revise capital spending plans,
resulting in reduced demand for capital equipment such as our products.  If
this oversupply is not reduced by increasing demand from the various
electronics industries that use semiconductors, which we cannot accurately
predict, our sales and profitability will be harmed.

Industry consolidation and outsourcing of semiconductor manufacturing may
reduce the number of our potential customers, harming our revenues.

	The substantial expense of building, upgrading or expanding a
semiconductor fabrication facility is increasingly causing semiconductor
companies to contract with foundries to manufacture their semiconductors.
In addition, consolidation and joint venturing within the semiconductor
manufacturing industry is increasing. We expect these trends to continue,
which will reduce the number of our potential customers.  This increased
concentration of our customers potentially makes our revenues more
volatile as a higher percentages of our total revenues are tied to a
particular customer's buying decisions.

If we fail to develop and introduce reliable new or enhanced products and
services that meet the needs of semiconductor manufacturers, our results
will suffer.

	Rapid technological changes in semiconductor manufacturing processes
require us to respond quickly to changing customer requirements. Our future
success will depend in part upon our ability to develop, manufacture and
successfully introduce new systems and product lines with improved
capabilities and to continue to enhance existing products, including products
that process 300 millimeter wafers. This will depend upon a variety of
factors, including new product selection, timely and efficient completion
of product design and development and of manufacturing and assembly
processes, product performance in the field and effective sales and
marketing. In particular:

* We must develop the technical specifications of competitive new systems, or
enhancements to our existing systems, and manufacture and ship these systems
or enhancements in volume in a timely manner.

* We will need to accurately predict the schedule on which our customers will
be ready to transition to new products, in order to accurately forecast demand
for new products while managing the transition from older products.

* We will need to effectively manage product reliability or quality problems
that often exist with new systems, in order to avoid reduced orders, higher
manufacturing costs, delays in acceptance and payment and additional service
and warranty expenses.

* Our new products must be accepted in the marketplace.

	Our failure to meet any of these requirements will have a material
adverse effect on our operating results and profitability.

If we fail to compete successfully in the highly competitive semiconductor
equipment industry, our sales and profitability will decline.

	The market for semiconductor manufacturing equipment is highly
competitive and includes companies with substantially greater financial,
engineering, manufacturing, marketing and customer service and support
resources than we have that may be better positioned to compete
successfully in the industry. In addition, there are smaller, emerging
semiconductor equipment companies that provide innovative systems with
technology that may have performance advantages over our systems.
Competitors are expected to continue to improve the design and
performance of their existing products and processes and to introduce
new products and processes with improved price and performance
characteristics. If we are unable to improve or introduce competing
products when demanded by the markets, our business will be harmed.
In addition, if competitors enter into strategic relationships with
leading semiconductor manufacturers covering products similar to those
sold or being developed by us, our ability to sell products to those
manufacturers may be adversely affected.

We have been dependent on sales to a limited number of large customers;
the loss of any of these customers or any reduction in orders from them
could materially affect our sales.

	Historically, we have sold a significant proportion of our
products and services to a limited number of fabricators of semiconductor
products. For example, in 2002, one of our customers, IBM, accounted for
14% of our net sales, and our top ten customers accounted for 64% of our
net sales. None of our customers has entered into a long-term agreement
requiring it to purchase our products. Although the composition of the
group comprising our largest customers has varied from year to year, the
loss of a significant customer or any reduction or delays in orders from
any significant customer, including reductions or delays due to customer
departures from recent buying patterns, or market, economic or competitive
conditions in the semiconductor industry, could adversely affect us. The
ongoing consolidation of semiconductor manufacturers may also increase
the harmful effect of losing a significant customer.

Our quarterly financial results may fluctuate significantly and may
fall short of anticipated levels.

	We derive most of our revenues from the sale of a relatively small
number of expensive products to a small number of customers. The list prices
on these products range from $200,000 to over $4.0 million. At our current
sales level, each sale, or failure to make a sale, could have a material effect
on us in a particular quarter. Our lengthy sales cycle, coupled with customers'
competing capital budget considerations, make the timing of customer orders
uneven and difficult to predict. In a given quarter, a number of factors can
adversely affect our revenues and results, including changes in our product
mix, increased fixed expenses per unit due to reductions in the number of
products manufactured, and higher fixed costs due to increased levels of
research and development and expansion of our worldwide sales and marketing
organization. Our gross margins also may be affected by the introduction of
new products. We typically become more efficient in producing our products
as they mature. For example, our gross margins in 2001 and 2002 were adversely
affected in part as a result of the increased proportion of systems sold to
process 300 millimeter wafers. In addition, our backlog at the beginning of
a quarter typically does not include all orders required to achieve our sales
objectives for that quarter and is not a reliable indicator of our future
sales. As a result, our net sales and operating results for a quarter depend
on our shipping orders as scheduled during that quarter as well as obtaining
new orders for products to be shipped in that same quarter. Any delay in, or
cancellation of, scheduled shipments or in shipments from new orders could
materially and adversely affect our financial results. Due to the foregoing
factors, we believe that period-to-period comparisons of our operating results
should not be relied upon as an indicator of our future performance.

We access the important Japanese market for ion implant through a joint venture
which we do not control.

We own 50% of the equity of a Japanese corporation called Sumitomo Eaton Nova
or SEN, to which we have granted an exclusive license to manufacture and sell
ion implanters in Japan.  The remaining 50% of the equity is owned by Sumitomo
Heavy Industries, Ltd., a Japanese manufacturer of industrial machinery and
shipbuilding.  Our joint venture agreement with Sumitomo gives both owners veto
rights, so that neither of us alone can effectively control SEN.  SEN's
business is subject to the same risks as our business.  Royalties and income
from SEN have been a substantial contribution to our earnings, and a
substantial decline in SEN's sales and income from operations could have a
material adverse effect on our net income.   As a result of this joint
venture structure, we have less control over SEN management than over our
own management and may not have timely knowledge of factors affecting SEN's
business.  In addition, given the equal balance of ownership, it is possible
that the SEN Board may be unable to reach consensus from time to time.
Neither Axcelis or Sumitomo has the right to buy out the other's interest
in SEN and the SEN joint venture is perpetual, although termination
provisions in the license agreement  allow either SEN or Axcelis to
effectively terminate the joint venture at the end of 2004.  SEN has been
a very valuable partner to Axcelis since its formation and we expect to
renew our license to SEN for a further 5 year term.

From time to time, we have allowed SEN to sell implanters outside of Japan.
We allow these sales when the customer requests SEN products.  Such requests
tend to occur when SEN customers participate, as joint venturers or technical
advisors, in fabrication facilities outside of Japan.  In those cases, the
financial benefit to Axcelis from the sale of a SEN implanter is less than the
financial  benefit of a sale of an Axcelis implanter, but our primary goal to
satisfy our customer with the product of their choice.  When these sales are
allowed, we act as exclusive agent for SEN to manage the terms of the sales
and to ensure that  they are consistent with our global product and customer
strategies.  We receive commissions from SEN on these extra-territorial sales
and assume most of the post-installation warranty responsibility.


A decline in sales of our products and services to customers outside the United
States would hurt our business and profits.

	We are substantially dependent on sales of our products and services
to customers outside the United States, which accounted for approximately
70%  62% and 51%, of our net sales in  2000 and 2001 and 2002, respectively.
We anticipate that international sales will continue to account for a
significant portion of our net sales. Because of our dependence upon
international sales, our results and prospects may be adversely affected by
a number of factors, including:

* unexpected changes in laws or regulations resulting in more burdensome
governmental controls, tariffs, restrictions, embargoes or export license
requirements;
* difficulties in obtaining required export licenses;
* volatility in currency exchange rates;
* political and economic instability, particularly in Asia;
* difficulties in accounts receivable collections;
* extended payment terms beyond those customarily offered in the United
States;
* difficulties in managing distributors or representatives outside the
United States;
* difficulties in staffing and managing foreign subsidiary and branch
operations; and
* potentially adverse tax consequences.

Making more sales denominated in foreign currencies to counteract the
strong dollar may expose us to additional risks that could hurt our results.

	Substantially all of our sales to date have been denominated in
U.S. dollars. Our products become less price competitive in countries with
currencies that are declining in value in comparison to the dollar. This
could cause us to lose sales or force us to lower our prices, which would
reduce our gross margins. Our equity income and royalty income from SEN are
denominated in Japanese yen, which exposes us to some risk of currency
fluctuations.  If it becomes necessary for us to make more sales denominated
in foreign currencies to counteract the strong dollar, we will become more
exposed to these risks.

We may not be able to maintain and expand our business if we are not able to
retain, hire and integrate additional qualified personnel.

	Our business depends on our ability to attract and retain qualified,
experienced employees. There is substantial competition for experienced
engineering, technical, financial, sales and marketing personnel in our
industry. In particular, we must attract and retain highly skilled design
and process engineers. Competition for such personnel is intense,
particularly in the areas where we are based, including the Boston
metropolitan area and the Rockville, Maryland area, as well as in other
locations around the world. If we are unable to retain our existing key
personnel, or attract and retain additional qualified personnel, we may
from time to time experience levels of staffing inadequate to develop,
manufacture and market our products and perform services for our customers.
As a result, our growth could be limited or we could fail to meet our
delivery commitments or experience deterioration in service levels or
decreased customer satisfaction, all of which could adversely affect our
financial results and cause the value of our notes and stock to decline.

Our dependence upon a limited number of suppliers for many components and
sub-assemblies could result in increased costs or delays in manufacture and
sales of our products.

	We rely to a substantial extent on outside vendors to manufacture
many of the components and subassemblies of our products. We obtain many of
these components and sub-assemblies from either a sole source or a limited
group of suppliers. Because of our reliance on outside vendors generally,
and on a limited group of suppliers in particular, we may be unable to
obtain an adequate supply of required components on a timely basis, on
price and other terms acceptable to us, or at all.

	In addition, we often quote prices to our customers and accept
customer orders for our products before purchasing components and
subassemblies from our suppliers. If our suppliers increase the cost of
components or subassemblies, we may not have alternative sources of supply
and may not be able to raise the price of our products to cover all or
part of the increased cost of components.

	The manufacture of some of these components and subassemblies is
an extremely complex process and requires long lead times. As a result, we
have in the past and may in the future experience delays or shortages. If
we are unable to obtain adequate and timely deliveries of our required
components or subassemblies, we may have to seek alternative sources of
supply or manufacture these components internally. This could delay our
ability to manufacture or to ship our systems on a timely basis, causing
us to lose sales, incur additional costs, delay new product introductions
and suffer harm to our reputation.


In certain circumstances, we may need additional capital.

	Our capital requirements may vary widely from quarter to quarter,
depending on, among other things, capital expenditures, fluctuations in
our operating results, financing activities, acquisitions and investments
and inventory and receivables management. We believe that our available
cash, our credit line and our future cash flow from operations will be
sufficient to satisfy our working capital, capital expenditure and research
and development requirements for the foreseeable future. This, of course,
depends on the accuracy of our assumptions about levels of sales and
expenses, and a number of factors, including those described in these
"Risk Factors," could cause us to require additional capital from external
sources. In addition, in the future, we may require or choose to obtain
additional debt or equity financing in order to finance acquisitions or
other investments in our business. Depending on market conditions, future
equity financings may not be possible on attractive terms and would be
dilutive to the existing holders of our common stock and convertible notes.
Our existing credit agreement contains restrictive covenants and future debt
financings could involve additional restrictive covenants, all of which  may
limit the manner in which we conduct our business.

We may incur costly litigation to protect our proprietary technology, and
if unsuccessful, we may lose a valuable asset or experience reduced market
share.

	We rely on a combination of patents, copyrights, trademark and
trade secret laws, non-disclosure agreements and other intellectual
property protection methods to protect our proprietary technology.
Despite our efforts to protect our intellectual property, our competitors
may be able to legitimately ascertain the non-patented proprietary technology
embedded in our systems. If this occurs, we may not be able to prevent their
use of this technology. Our means of protecting our proprietary rights may
not be adequate and our patents may not be sufficiently broad to prevent
others from using technology that is similar to or the same as our technology.
In addition, patents issued to us have been, or might be challenged, and might
be invalidated or circumvented and any rights granted under our patents may
not provide adequate protection to us. Our competitors may independently
develop similar technology, duplicate features of our products or design
around patents that may be issued to us. As a result of these threats to
our proprietary technology, we may have to resort to costly litigation to
enforce or defend our intellectual property rights.

	On January 8, 2001, we filed a lawsuit against Applied Materials,
Inc. ("Applied") in the United States District Court for the District of
Massachusetts. The complaint alleges that Applied's medium current/high
energy ion implanter machine launched in November 2000 infringes our patent
for ion implantation equipment using radio frequency linear accelerator
technology. We have also alleged that Applied unlawfully interfered with
our existing and future contracts. On January 18, 2001, we filed a motion
for a preliminary injunction for the reason, among others, that
infringement at the time of industry transition between equipment
capable of handling 200 millimeter wafers and equipment capable of
handling 300 millimeter wafers would irreparably harm us. Through
this motion, we asked the court to stop Applied from manufacturing,
selling or offering to sell its medium current/high energy ion implanter
machine and to order Applied to remove all our patented technology from
implanters that Applied may have placed in chipmakers' plants for process
development trials. Applied filed counterclaims of unfair competition,
defamation and tortious interference with prospective economic
advantage, all of which, it contends, arise from certain communications
we allegedly made about the lawsuit and its claims of infringement.

	In December 2002 the court issued  a claim construction,
interpreting the scope of our patent.  In March 2003 the court made
summary judgement rulings in light of the claim construction, narrowing
the scope of the infringement issues to be determined by a jury in a
trial set for June 2003.   We believe our claims are meritorious and
intend to pursue the matter vigorously. Although there can be no
assurance of a favorable outcome and we have incurred significant legal
expenses to pursue this litigation, we do not believe that our pursuit
of this matter will have a material adverse effect on our financial
condition, results of operations or liquidity. In the event that Applied
is found not to have infringed, we expect that Applied will continue to
sell its medium current/high energy implanter as a new and substantial
competitor for sales of high energy/medium current ion implantation
equipment.

We might face intellectual property infringement claims or patent
disputes that may be costly to resolve and, if resolved against us,
could be very costly to us and prevent us from making and selling
our systems.

	From time to time, claims and proceedings have been or
may be asserted against us relative to patent validity or
infringement matters. Our involvement in any patent dispute or
other intellectual property dispute or action to protect trade
secrets, even if the claims are without merit, could be very
expensive to defend and could divert the attention of our management.
Adverse determinations in any litigation could subject us to significant
liabilities to third parties, require us to seek costly licenses from
third parties and prevent us from manufacturing and selling our systems.
Any of these situations could have a material adverse effect on us and
cause the value of our common stock to decline.